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GENERAL INTRODUCTION 
The total synthesis of natural products continues to be a valuable tool for the 
development of new pharmaceuticals.  Important classes of natural products towards this 
end include alkaloids, terpenoids, polyketides, polyphenols and others, which have inspired 
countless synthetic efforts based on their array of biological activity and remarkable 
scaffolds.  Skilled synthetic chemists need to be mindful of not only completing their target 
but doing so that in a way that is elegant and insightful to those in the synthetic community.  
The interface between organic and medicinal chemistry provides an avenue for synthetic 
chemists to do creative, thought-provoking work that is also biologically relevant.  In this 
context, we have investigated the synthesis of polyphenols (±)-1,3,4,5-tetragalloylapiitol, 
ellagitannins and flavonols and the construction of the alkaloid azafluorenones. 
Chapter one describes the total synthesis of (±)-1,3,4,5-tetragalloylapiitol.  Our 
synthesis provides the shortest route to this polyphenolic compound.   
The synthesis of natural and unnatural ellagitannins is discussed in chapter two.  A 
key oxidative C-C bond between gallic acid moieties is explored.   
The third chapter focuses on a base-mediated cyclization step towards the synthesis 
of flavonols.  This method is vastly different than the current methods for their synthesis.   
The synthesis of azafluorenones is examined in chapter four.  An intramolecular 
Heck reaction is used to close the core of these 6-5-6 tricyclic alkaloids. 
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CHAPTER 1. Total synthesis of (±)-1,3,4,5-tetragalloylapiitol 
 
Introduction: 
Human Immunodeficiency virus (HIV) is responsible for the development of acquired 
immunodeficiency syndrome (AIDS).1  The World Health Organization (WHO) has classified 
AIDS as a pandemic, meaning that the disease is not only widespread, but also actively 
spreading. Two types of HIV have been characterized; HIV type 1 (HIV-1) and HIV type 2 
(HIV-2).  HIV-1 has been found to be more prevalent because of its ability to invade the 
host’s genome without being detected.  In 2007, AIDS is estimated to have killed 2.1 million 
people, largely in the underdeveloped countries which have limited access to current 
antiretroviral treatments (WHO 2007). Particularly affected by this pandemic is Sub-Saharan 
Africa, which has just over 12% of the world’s population but accounts for two-thirds of the 
population infected with HIV (UN AIDS Report 2011).  Without treatment, the average 
patient with HIV develops AIDS in 9 to 10 years.  The average survival rate after acquiring 
AIDS is only 9 months.2  Although the disease can be controlled with proper treatment, the 
high costs associated with the current drug treatments severely limits this option in 
underdeveloped countries.  
HIV is a lentivirus, a retrovirus that uses the reverse transcriptase enzyme to make a 
genetic DNA copy from its RNA genome.  Retroviruses, as the name would indicate, 
replicate in the opposite fashion of most viruses, which produce RNA from DNA.  Once 
infected, HIV attaches to the glycoproteins that reside on the outside of CD4+ T cells.  
Eventually the viral envelope fuses with the cell membrane causing the release of the virus 
into the cell.3  After penetrating the cell, HIV reverse transcriptase copies the viral RNA into 
complementary DNA (cDNA).4  cDNA proceeds to make a genetic copy and then integrates 
itself into the host cell’s DNA via the integrase enzyme.  When the proper transcription 
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factors are present, the virus begins to replicate itself into messenger RNA (mRNA),5 and 
fragments of this mRNA are released into the cytoplasm for the production of proteins.6  
Regulatory proteins synthesized from the mRNA, Tat and Rev, are instrumental in allowing 
the unspliced RNA to leave the nucleus intact.6  If splicing of the RNA in the nucleus were to 
occur, it would destroy the viral RNA copy needed for replication, thereby ending the 
lifecycle of the virus.  However, if splicing does not occur, the structural proteins Gag and 
Env are produced.  The Gag protein provides the structural elements of the virus, while the 
Env protein is responsible for the formation of the viral envelope of the new virus. These 
newly created proteins help shuttle the virus out of the cell through the plasma membrane 
and allow it to infect another CD4+ T cell. 
Although the replication cycle of HIV has numerous intricate pathways, researchers 
have not found a way to completely inhibit any of these pathways.  The HIV virus replicates 
about 1010 times each day, and coupled with a high mutation rate, the virus’s genome 
changes significantly, which allows HIV to quickly develop resistances to antiviral 
pharmaceuticals.7  Another challenge of the disease is that most patients with HIV are 
unaware they are infected with the disease.8  Initially, people suffer from an acute infection 
and experience many of the same symptoms of the common cold, including, fever, sore 
throat and muscle pain among others.  This is followed by the latency period or the 
incubation period, where few, if any, symptoms are present.  This period can last for weeks 
up until years, allowing the infected patient plenty of time to unknowingly spread the disease.  
After this incubation period, the patient contracts AIDS which is dictated by the CD4+ T cell 
counts.   
While no cure exists for HIV/AIDS, there are treatment options available to slow the 
development of AIDS from HIV.  Currently, patients take a cocktail of different drugs in 
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conjunction, referred to as Highly Active Antiretroviral Therapy (HAART).  These drugs 
target an array of enzymatic pathways, including entry inhibitors, CCR5 receptor antagonists, 
nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase 
inhibitors (NNRTI), protease inhibitors, integrase inhibitors, and maturation inhibitors.  
Multiple targets are necessary; if any of these drugs were taken independently, rapid 
mutation rates would lead to drug resistance.  Combination therapy slows replication on 
many enzymatic fronts to minimize drug resistance.  Unfortunately, not all these drugs work 
together effectively, so drug makers are constantly improving the combinations to be more 
advantageous.  Overall, treatment of HIV is limited by drug intolerance9 and virus 
resistance.10 
 Many different enzymatic pathways have been exploited for drugs against HIV, but 
inhibition of ribonuclease H (RNase H) has been left unexplored as a treatment option.11  
During reverse transcription, RNase H is needed to cleave the RNA strand from the 
RNA/DNA heteroduplex.12  Inhibition of this enzyme would hamper or shut down the ability 
of the virus to replicate.13,14  Gustafson and coworkers at the NIH created a screening 
campaign of over 82,000 compounds and isolated 1,3,4,5-tetragalloylapiitol (1, Figure 1) 
from the plant Hylodendron gabuunensi.  The compound inhibited HIV-1, HIV-2 and human 
RNase H with IC50 values of 0.24, 0.13 and 1.5 μM respectively.
15  They were able to 
elucidate the gallic acid moieties of 1 by 1H NMR and 13C NMR.  Gallic acid (3) has been 
widely used for medicinal purposes because of its anti-fungal and anti-viral properties.16  It is 
also prevalent in tannins, which have been extensively characterized and studied.  Further 
examination of 1 using  heteronuclear multiple bond correlation (HMBC) revealed an apiitol 
core (2).15  This is the first example of apiitol being isolated as a secondary metabolite in 
nature.  Apiitol is the reduced form of D-apiose which is found in plant cell wall 
polysaccharides.17  
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Figure 1. The structures of (-)-1,3,4,5-tetragalloylapiitol (1), apiitol (2) and gallic acid (3) 
 
Results and Discussion: 
Our impetus for this project was the significant biological activity of (-)-1,3,4,5-
tetragalloylapiitol (1) and its unusual structure.  Our initial retrosynthesis analysis of the 
compound was cognizant of the polar nature of this molecule.  We wanted to protect the 12 
gallic acid phenols as benzyl ethers to prohibit protecting group translocation, which is 
known for other phenol protecting groups, and allow for facile global deprotection.  In 
addition, we also wanted to add the protected gallic acid moieties two at a time to maintain 
organic solubility throughout the synthesis.  With this in mind, we envisioned the benzyl  
 
Scheme 1. The retrosynthesis of 1,3,4,5-tetragalloylapiitol (1). Ar = 3,4,5-O-benzylgalloyl 
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protected intermediate 4 coming from bis-acylated product 5 (Scheme 1).  This compound 
would derive from bis-TBS-protected apiitol 6.  The core of the sugar would be generated 
from dihydroxylation of 7, which in turn, would be obtained by vinyl addition to the known 
TBS ether 8.         
The extensive use of gallates in the synthesis of tannins provided an efficient route to 
the 3,4,5-O-benzylgallic acid (11).18  Readily known methyl gallate 9 was benzyl protected to 
afford intermediate 10 (Scheme 2).  The compound was hydrolyzed to give 11.18   
 
Scheme 2. The synthesis of trisbenzyl protected gallic acid 11. 
 
Our synthesis commenced with the formation of the bis-TBS ether 13 from 
commercially available 1,3-dihydroxyacetone dimer (12, Scheme 3).19  Addition of 
vinylgrignard at sub-ambient temperatures afforded the terminal olefin 14, which was  
 
Scheme 3. Synthesis of 15 from commercially available dihydroxyacetone dimer (12). 
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dihydroxylated with catalytic osmium tetraoxide (OsO4) and trimethylamine N-oxide 
dihydrate (TMNO) in 55% yield to furnish the protected apiitol intermediate 15. 
Steglich esterification of triol 15 with acid 11 rendered the desired diacylated product 
16 along with a complex mixture of acylated materials (Scheme 4).  Difficulty in purification 
and characterization made proper identification of the acylated products challenging.  We 
postulated that we were generating a mixture of mono-, di- or triacylated compounds.  To 
alleviate this problem, we decided to make two changes to our synthesis:  
1. Protection of the tertiary alcohol:  The tertiary alcohol would be selectively protected 
as a benzyl ether to eliminate the potential acylation of the tertiary alcohol.  
2. Use of the tribenzylgallic acid chloride rather than acid 11:  The more electrophilic 
acid chloride will provide a more reactive material to drive the reaction to completion.  
 
Scheme 4.  Steglich esterification of 15 with acid 11. Ar = 3,4,5-O-benzylgalloyl 
 
We protected the tertiary alcohol 14 by the action of sodium hydride, catalytic 
tetrabutylammonium iodide (TBAI) and benzyl bromide (BnBr) to give olefin 17 (Scheme 5).  
If TBAI was not included, the reaction yield was less than 10%.  Dihydroxylation with 
catalytic OsO4 gave diol 18.  Acid 11 was converted to the corresponding acid chloride 19 
under mild conditions with oxalyl chloride.18  Gratifyingly, treating diol 18 with acid chloride 
19 afforded the desired digallate 20 cleanly and in 83% yield. 
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Scheme 5. Synthesis of intermediate 20 through dihydroxylation and benzyl protection of 14. Ar = 
3,4,5-O-benzylgalloyl 
 
After obtaining 20, we focused our attention toward the removal of the TBS ethers.  
Initial attempts with tetrabutylammonium fluoride (TBAF) buffered with acetic acid proved 
unsuccessful.  Either we recovered the starting material or under more rigorous conditions 
the esters were cleaved.  Deprotection of the silyl ethers was achieved using HF·pyridine, 
which was selective for the deprotection of the silyl groups (Scheme 6).20  Without further  
 
Scheme 6. Synthesis of protected intermediate 22. Ar = 3,4,5-O-benzylgalloyl 
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purification, crude diol 21 was coupled with acid chloride 19 to generate benzyl protected 
intermediate 22 in excellent yield. 
Global deprotection of the benzyl groups was carried out with palladium on carbon 
under a hydrogen atmosphere to furnish the racemic natural product 1 in 25% yield 
(Scheme 7).  The low yield was the result of recrystallizing on a 30 mg scale.  Overall, the 
natural product was formed in 8 steps and 5% overall yield.21  Characterization data of 
product 1 was in excellent agreement with that literature values.15    
 
Scheme 7. Completion of the total synthesis of 1. Ar = 3,4,5-O-benzylgalloyl 
 
Upon completion of 1, we became aware of another synthesis of this molecule by 
Argade’s group.22  Their synthesis had similarities including the use of the 3,4,5-O-
benzylgallic acid 11 and the generation of the esters in iterations to maintain organic 
solubility.  However, their synthesis used a different route to construct the apiitol core.  Their 
synthesis began with methanolysis of commercially available citriconic anhydride (23, 
Scheme 8).  Subsequent allylic bromination with N-Bromosuccinimide (NBS) gave allylic 
bromide 24, and nucleophilic substitution of 24 with sodium acetate formed the allylic 
acetate 25.  Dihydroxylation with catalytic OsO4 produced a diol, which was protected with 
2,2-dimethoxypropane and catalytic para-toluenesulfonic acid (PTSA) to produce cyclic ketal 
26.  Triol 27 was formed from reduction of the esters using lithium aluminum hydride (LAH).  
Steglich esterification with acid 11 rendered 28, which followed by ketal deprotection with 
trifluoroacetic acid (TFA) and a second Steglich esterification produced protected 
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intermediate 29.  Hydrogenolysis at 65 psi of hydrogen and purification by column 
chromatography afforded racemic 1 in quantitative yield. They accomplished the total 
synthesis in 10 steps with 44% overall yield.     
 
Scheme 8. Argade’s synthesis of 1. Ar = 3,4,5-O-benzylgalloyl  
 
Argade’s synthesis provided some valuable information to improve our previous 
synthesis.  They were able to selectively use the Steglich esterification conditions to go from 
29 to 4 without protection of the tertiary alcohol.  Furthermore, esterification of 27 to 28 was 
complete and did not lead to a mixture of different acylated products.  With this in mind, we 
decided to reexamine our previous reaction from 15 to 16 using Argade’s conditions.  The 
amount of carbodiimide was doubled and the temperature of the reaction was increased to 
boiling dichloromethane, these conditions afforded compound 16 as a single product 
(Scheme 9).  For comparison, this reaction was also attempted using the conditions we had 
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used previously, which had resulted in a complex mixture of products (Scheme 4).  After 
exhaustive preparative TLC separations, we were able to separate 16 and monoacylated 30.  
This result validated that it was unnecessary to protect the tertiary alcohol and our previous 
mixture had been the result of incomplete coupling.   
 
Scheme 9. Studies of the Steglich Esterification with triol 15. Ar = 3,4,5-O-benzylgalloyl 
 
Deprotection of diester 16 with HF·pyridine yielded 31 (Scheme 10).  The polarity of 
31 made it difficult to purify, so the crude material was taken to the next step without further 
purification.  Esterification of this crude material gave us the protected intermediate 4.  A 
subsequent and quantitative global deprotection, as shown in Argade’s synthesis (Scheme 
8), would afford the target molecule 1 in quantitative yield, which constituted a formal  
 
Scheme 10.  Synthesis of protected intermediate 4.  Ar = 3,4,5-O-benzylgalloyl 
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synthesis of compound 1.  We accomplished the advanced intermediate 4 in 6 steps in 23% 
overall yield.21  This second generation synthesis accomplished the synthesis in one fewer 
step and avoided the use of the acid chloride 19.   
Since our completion of this synthesis, further research has been done on this 
intriguing molecule.  Argade and co-workers continued their pursuit of 1 by accomplishing 
the first asymmetric synthesis of the compound.23  They utilized a key chemoenzymatic 
resolution that made enatiopure (-)-32 (Scheme 11).  This intermediate was carried through 
a similar sequence of reactions as their previous synthesis to generate (-)-1.  Overall, their 
synthesis was accomplished in 9 steps with an overall yield of 5%.23  
 
Entry Enzyme Temp/Time 
Yield (%)  
(-)-32/ee  
a PPL 25 °C, 48 h NR 
b PPL 35 °C, 48 h NR 
c CCL 25 °C, 48 h NR 
d CCL 35 °C, 48 h 57/25 
e Amano PS 25 °C, 96 h 83/N/A 
f Amano PS 35 °C, 8 days 44/95 
g Amano PS 50 °C, 84 h 42/97 
 
Scheme 11. Chemoenzymatic resolution of compound 32.   Pig pancreas lipase (PPL), Candida 
cylindracea lipase (CCL), Pseudomonas cepacia lipase (Amano PS). 
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Kojima and coworkers group also accomplished an asymmetric synthesis of (-)-1 by 
starting with commercially available L-ribose (35).24  In 5 steps, they were able to synthesize 
L-apiitol (S)-2. Coupling of (S)-2 with acid chloride 19, followed by global deprotection, 
generated (S)-1 (Scheme 12).  However, when they compared optical rotations of this 
compound to those of the natural product, they were opposite in direction.  To further 
understand this discrepancy, they synthesized (R)-2 from D-Ribose (36).  Esterificaiton with 
19 and hydrogenolysis produced (R)-1.  This compound had excellent agreement with the 
optical rotations reported by Gustafson, which indicated that their synthesis generated the 
(R)-1 enantiomer rather than (S)-1 as reported previously by Argade and coworkers.15 
 
Scheme 12. Synthesis of (S)-1, however they proposed the absolute configuration is (R)-1 based on 
optical rotation of the extracted natural product. 
 
Since its isolation 5 years ago, 1 has inspired four synthetic efforts.  It is a popular 
synthetic target due to its encouraging biological activity and unique structure.  Despite 
these newer syntheses, our 7-step synthesis is still tied for the shortest route toward the 
natural product.  In addition, our synthesis is amendable to different derivatives including 
different mono-, di- and triacylated galloylapiitols for future biological studies.   
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Experimental: 
 
1,3-Bis[(tert-butyldimethylsilyl)oxy]-2-propanone (13). To a stirred solution of 
dihydroxyacetone dimer (12) (4.000 g, 22.20 mmol) in DMF (30 mL) were added imidazole 
(7.558 g, 111.0 mmol) and tert-butyldimethylsilyl chloride (16.73 g, 111.0 mmol) at 0 °C.  
The mixture was stirred at rt for 1 h and then water (30 mL) was added at 0 °C.  The 
reaction mixture was extracted with ethyl acetate (3 × 20 mL), washed with brine (30 mL), 
dried (MgSO4), filtered, and concentrated.  The residue was purified by flash column 
chromatography (hexanes) to give 13 (12.56 g, 89% yield) as a colorless oil. 1H NMR (300 
MHz, CDCl3) δ: 0.10 (s, 12 H), 0.93 (s, 18 H), 4.42 (s, 4 H).  
 
4-tert-Butyldimethylsilyloxy-3-tert-Butyldimethylsilyloxymethyl-1-buten-3-ol. (14).  To 
a stirred solution of vinylmagnesium bromide solution (1M in THF) (9.41 mL, 9.41 mmol) in 
15 mL of THF at -30 °C, a solution of the protected ketone 13 (1.000 g, 3.138 mmol) in THF 
(10 mL) was added dropwise.  The mixture was then stirred at -30 °C for 3 h and then 
saturated aqueous NH4Cl (20 mL) was added to the mixture.  The reaction mixture was 
extracted with EtOAc (3×10 mL), washed with brine (10 mL), dried (MgSO4), filtered and 
concentrated.  The residue was purified by flash column chromatography (hexanes-ethyl 
acetate, 10:1) to give 14 (0.794 g, 73% yield) as a colorless oil:  1H NMR (300 MHz, CDCl3) 
δ: 0.06 (s, 12 H), 0.90 (s, 18 H), 2.71 (s, 1 H), 3.54 (dd, J = 29.7 and 9.3 Hz, 4 H), 5.19 (dd, 
J = 11.1 and 1.8 Hz, 1 H), 5.42 (dd, J = 17.4 and 1.8 Hz, 1 H), 5.96 (dd, J = 17.5 and 10.8 
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Hz, 1 H); 13C NMR (100 MHz, CDCl3): -5.24, 18.5, 26.1, 65.9, 75.0, 114.9, 138.7; MS m/z 
347 (M+).  
 
4-tert-Butyldimethylsilyloxy-3-tert-butyldimethylsilyloxymethyl-3-hydroxybutane-1,2-
diolbis3,4,5-tris(benzyloxy)benzoate (15).  To a solution of olefin 14 (1.500 g, 4.326 
mmol), trimethylamine N-oxide dihydrate (0.962 g, 8.65 mmol), and osmium tetraoxide 
solution (10 mg/1.0 mL) (4.40 mL 0.216 mmol) in acetone (80 mL) and water (40 mL) was 
stirred at rt for 7 hours.  The reaction was quenched with saturated sodium sulfite solution 
(100 mL) and stirred for 0.5 h, concentrated, and extracted with CH2Cl2 (3 × 50 mL), and the 
combined organic layers were washed with brine (50 mL), dried (MgSO4), filtered and 
concentrated.  The residue was purified by flash chromatography (hexanes, ethyl acetate) to 
give 15 (0.9052 g, 55% yield) as a colorless oil.  1H NMR (300 MHz, CDCl3) δ: 0.10 (s, 12 H), 
0.90 (s, 18 H), 2.86 (t, J = 6.9 Hz, 1 H), 3.05 (d, J = 5.4 Hz, 1 H), 3.35 (s, 1 H), 3.57 – 3.90 
(m, 7 H) 
 
3-(benzyloxy)-4-(tert-butyldimethylsilyloxy)-3-(tert-butyldimethylsilyloxymethyl) 
butane-1,2-diol (17).  To a suspension of NaH (0.243 g 60% dispersion in mineral oil, 6.07 
mmol) in THF (20 mL) was added a solution of alcohol 14 (1.915 g, 5.522 mmol) in THF (10 
mL) at 0 °C.  The mixture was stirred at 0 °C for 20 minutes.  Tetrabutylammonium iodide 
(204 mg, 0.552 mmol) and benzyl bromide (0.72 mL, 6.1 mmol) were added.  The mixture 
was allowed to warm to rt and was stirred for 18 h.  The reaction was quenched with a 
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saturated aqueous solution of NH4Cl (20 mL) and diluted with ethyl acetate (20 mL).  After 
extraction with ethyl acetate (3×10 mL), the combined organic extracts were washed with 
brine (20 mL), dried (MgSO4), filtered, and concentrated.  The residue was purified by flash 
chromatography (hexanes) to give the benzyl ether 17 (1.665 g, 69% yield) as a colorless 
oil.  :  1H NMR (300 MHz, CDCl3) δ: 0.06 (s, 12 H), 0.90 (s, 18 H), 3.67 (d, J = 9.9 Hz, 2 H), 
3.85 (d, J = 9.6 Hz, 2 H), 4.55 (s, 2 H), 5.29 (dd, J = 8.1 Hz, J = 1.6 Hz, 1 H), 5.34 (dd, J = 
14.9 Hz, J = 1.6 Hz, 1 H), 5.84 (dd, J = 18.0 Hz, J = 11.1 Hz, 1 H), 7.39-7.25 (m, 5 H)   
 
3-(benzyloxy)-4-((tert-butyldimethylsilyl)oxy)-3-(((tert-butyldimethylsilyl)oxy)methyl)- 
butane-1,2-diol (15). A solution of benzyl ether 17 (1.401 g, 3.207 mmol), trimethylamine N-
oxide dihydrate (0.713 g, 6.41 mmol), and osmium tetroxide solution (10.0 mg/1.0 mL) 
(0.160 mmol, 4.07 mL) in acetone (90 mL) and water (45 mL) was stirred at rt for 7 h.  The 
reaction was quenched with a saturated sodium sulfite solution (100 mL), stirred for 0.5 h, 
concentrated, and extracted with CH2Cl2 (3×50 mL).  The combined organic layers were 
washed with brine (50 mL), dried (MgSO4), filtered and concentrated.  The residue was 
purified by flash chromatography (hexanes, ethyl acetate 5:1) to give 15 (0.911 g, 61% yield) 
as a colorless oil:  1H NMR (300 MHz, CDCl3) δ: 0.10 (s, 12 H), 0.92 (s, 18 H), 2.87 (m, 1 H), 
3.27 (d, J = 29.7 and 9.3 Hz, 4 H), 3.91 (m, 7 H), 4.71 (dd, J = 17.4 and 1.8 Hz, 2 H), 7.32 
(m, 5 H); 13C NMR (100 MHz, CDCl3): -5.44, 18.3, 26.0, 62.6, 63.0, 63.1, 66.1, 72.9, 80.0, 
127.6, 128.5, 139.1; MS m/z 493 (M+ + Na). 
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3-benzyloxy-4-tert-butyldimethylsilyloxy-3-(tert-butyldimethylsilyloxymethyl) butane-
1,2-diol bis-3,4,5-tris(benzyloxy)benzoate (20).  To a solution of diol 18 (0.456 g, 0.972 
mmol), DMAP (0.475 g, 3.89 mmol) in CH2Cl2 (40 mL) was added 3,4,5-
tris(benzyloxy)benzoyl chloride (19) (1.784 g, 3.886 mmol).  The reaction was stirred at rt for 
8 h.  The solvent was evaporated and chromatography of the residue (hexanes, ethyl 
acetate 10:1) to give 20 (1.094 g, 83% yield) as a colorless oil:  1H NMR (300 MHz, CDCl3) δ: 
0.10 (s, 12 H), 0.94 (s, 18 H), 3.83-4.08 (m, 4 H), 4.81-5.13 (m, 15 H), 6.05 (dd, J = 8.6, and 
3.6 Hz, 1 H), 7.27-7.39 (m, 39 H); 13C NMR (100 MHz, CDCl3): -5.4, 18.4, 26.1, 61.6, 62.5, 
66.3, 71.1, 71.2, 72.7, 75.2, 75.3, 80.6, 109.0, 109.3, 109.3, 125.2, 125.3, 127.5, 127.8, 
128.1, 128.2, 128.3, 128.4, 128.5, 128.6, 136.6, 136.8, 137.6, 137.7, 139.1, 142.3, 142.8, 
152.6, 152.7, 165.4, 166.1; MS m/z 1339 (M+ + Na). 
 
3-Benzyloxy-3-3,4,5-tris(benzyloxy)benzoyloxymethylbutane-1,2,4-trioltris(3,4,5-
tris(benzyloxy)benzoate) (21).  To a solution of protected alcohol 20 (0.459 g, 0.350 mmol) 
in dry THF (6 mL) and pyridine (6 mL) cooled to 0°C was added HF·pyridine (2.0 mL).  The 
reaction mixture was warmed to rt and stirred for 18 h.  The mixture was then diluted with 
EtOAc (5 mL) and washed with 10% aqueous CuSO4 (5 mL).  The aqueous phase was 
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extracted with EtOAc (3 × 5 mL) and then combined organics washed with saturated 
aqueous NaHCO3 (10mL) and dried over MgSO4.  The solvent was removed in vacuo to 
afford 21 as a yellow oil.  1H NMR (300 MHz, CDCl3) δ: 2.47 (br, 1 H), 2.71 (br, 1 H), 3.96-
3.81 (m, 4 H), 4.72-5.92 (m, 16 H), 5.94 (d, J = 9.0 Hz, 1 H), 7.22 – 7.39 (m, 39 H).  
 
3-(benzyloxy)-3-(((3,4,5-tris(benzyloxy)benzoyl)oxy)methyl)butane-1,2,4-triyltris(3,4,5-
tris(benzyloxy)benzoate) (22). To a solution of crude diol 21 (0.350 mmol) and DMAP 
(0.228g, 1.86 mmol) in CH2Cl2 (20mL) was added 3,4,5-tris(benzyloxy)benzoyl chloride(19) 
(0.855 g, 1.86 mmol).  The reaction was stirred at rt for 8 hours.  The solvent was 
evaporated and chromatography of the residue (CH2Cl2, ethyl acetate 10:1) gave 22 (0.554 
g 86% yield over 2 steps) as a colorless oil:  1H NMR (300 MHz, CDCl3) δ: 4.39-5.16 (m, 33 
H), 6.17 (dd, J = 7.0 and 3.0 Hz, 1 H), 7.26-7.43 (m, 73 H); 13C NMR (100 MHz, CDCl3): 
62.1, 63.1, 63.3, 66.5, 71.2, 71.3, 71.7, 75.3, 78.6, 109.0, 109.1, 109.3, 124.3, 124.4, 124.7, 
127.5, 127.6, 127.7, 127.9, 128.2, 128.3, 128.4, 128.6, 128.7, 136.5, 136.6, 136.7, 136.8, 
137.5, 137.6, 137.7, 137.8, 142.7, 142.8, 143.0, 143.2, 151.0, 152.7, 152.8, 165.2, 165.4, 
165.6, 165.9; MS m/z 1933 (M+). 
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1,3,4,5-Tetragalloylapiitol (1).  A suspension of benzylprotected tetragalloylapiitol (0.249 g, 
0.129 mmol), 10% Pd/C (25 mg) in 15 mL of dry THF was stirred at 40 °C under a hydrogen 
gas atmosphere for 16 h.  The reaction mixture was cooled and filtered through Celite, and 
the filtrate was evaporated.  The residue was crystallized from toluene/ethyl acetate.  
Compound 1 (26 mg, 26% yield) was obtained as colorless crystals.  Spectral data is in 
complete agreement with literature values.    
 
4-((tert-butyldimethylsilyl)oxy)-3-(((tert-butyldimethylsilyl)oxy)methyl)-3-
hydroxybutane-1,2-diyl bis(3,4,5-tris(benzyloxy)benzoate) (16). To a solution of triol 15 
(0.401 g, 1.053 mmol) was added 3,4,5-tris(benzyloxy)benzoic acid (11) (0.401 g, 1.053 
mmol), DCC (0.861 g, 4.21 mmol) DMAP (0.283 g, 2.32 mmol) in CH2Cl2 (20 mL).  The 
solution was refluxed for 2 h.  The solvent was evaporated and chromatography of the 
residue (5:1 hexanes, ethyl acetate) furnished 16 (1.035 g, 80.20% yield) as a colorless oil:  
1H NMR (300 MHz, CDCl3) δ: 0.11 (s, 12 H), 0.89 (s, 18 H), 3.62-4.74 (m, 4 H), 4.98-5.10 (m, 
13 H), 6.05 (dd, J = 96, and 2.4 Hz, 1 H), 7.269-7.382 (m, 34 H); 13C NMR (100 MHz, 
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CDCl3): -5.3, 18.4, 26.0, 60.6, 63.4, 63.3, 64.2, 71.2, 71.3, 73.2, 75.3, 75.3, 109.1, 109.4, 
125.1, 125.3, 127.7, 127.9, 128.1, 128.3, 128.6, 128.7, 136.7, 136.8, 137.6, 137.7, 142.5, 
142.9, 152.6, 152.7, 165.6, 166.1; MS m/z 1248 (M+ + Na). 
 
3-Hydroxy-3-(3,4,5-tris-benzyloxy)benzoyloxymethylbutane-1,2,4-trioltris-3,4,5-tris-
benzyloxy)benzoate (31).  A solution 16  (0.160 g, 0.130 mmol) in dry THF (2.0 mL) and 
pyridine (2.0 mL) was cooled to 0°C and HF·pyridine (0.67 mL) was added.  The reaction 
mixture was warmed to rt and stirred for 18 h.  The mixture was then diluted with EtOAc (2 
mL) and washed with 10% aqueous CuSO4 (2 mL).  The aqueous phase was extracted with 
EtOAc (3 × 2 mL) and the combined organics washed with saturated aqueous NaHCO3 
(10mL) and dried over MgSO4.  The solvent was removed in vacuo to afford 31 as a yellow 
oil.  1H NMR (300 MHz, CDCl3) δ: 3.60-3.80 (m, 4 H), 4.96-5.07 (m, 14 H), 5.58 (dd, J = 8.7, 
and 2.7 Hz, 1 H), 7.21-7.37 (m, 34 H) 
 
3-hydroxy-3-(((3,4,5-tris(benzyloxy)benzoyl)oxy)methyl)butane-1,2,4-triyl-tris(3,4,5-
tris(benzyloxy)benzoate) (4). To crude 31 (0.130 mmol) was added 3,4,5-
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tris(benzyloxy)benzoic acid (11) (0.172 g, 0.391 mmol), DCC (0.106 g, 0.521 mmol), and 
DMAP (0.035 g, 0.286 mmol) in CH2Cl2 (5 mL).  The solution was boiled for 2 h.  The 
solvent was evaporated and chromatography of the residue (10:1 CH2Cl2, ethyl acetate) 
furnished 4 (0.213 g, 89% yield over 2 steps) as a colorless oil.  
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CHAPTER 2. Synthesis of ellagitannins 
 
Introduction: 
Tannins are defined as any polyphenolic compound that can bind and precipitate 
proteins and alkaloids.1  They are derived from plants where they play an important role in 
protection from predators and providing functional support.2  There are three main classes of 
tannins: hydrolyzable tannins, condensed tannins and phlorotannins.3  With nearly 1000 
different hydrolyzable tannins isolated and characterized, it constitutes the largest group of 
tannins found in nature.4,5   
The biosynthetic pathway of hydrolyzable tannins is believed to originate from β-
glucogallin (1) and gallic acid (2, Scheme 1).6  The acids couple to the hydroxy groups of 1 
to synthesize a polygallated glucose, in this case penta-O-galloyl-β-D-glucopyranose β-PGG 
(3).   Hydrolyzable tannins similar to 3 can have further derivatives made via intra- or 
intermolecular oxidative C-C biaryl and C-O diaryl ether bond couplings.7,8,9   
 
Scheme 1. Proposed biosynthetic pathway of hydrolyzable tannins. 
 
There are two classes of hydrolyzable tannins: gallotannins and ellagitannins. 
Ellagitannins possess a 6,6’-dicarbonyl-2,2’,3,3’,4,4’-hexahydroxylbiphenyl moiety (4), or 
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simply hexahydroxydiphenoyl (HHDP), which when hydrolyzed, forms ellagic acid (5), the 
namesake of ellagitannins (Scheme 2).     
 
Scheme 2. Rapid lactonization of HHDP (4) to form ellagic acid (5). 
 
Since this initial classificiation, ellagitannins have been further classified by Haslam 
and later Okuda.6,10  Okuda’s classification system is based on the level of oxidation of the 
gallic acid moieties (Figure 1). Thus, ellagitannins can be classified into four classes:  
Type I: Gallotannins, which feature a glucose core with a varying degree of galloyl 
esters attached to either the sugar or through depside bonds (6).11   
Type II: Contain the HHDP moiety with no further oxidation products (7). 
Type III: Posses the dehydrohexahydroxydiphenoyl (DHHDP) subunit which is 
derived from oxidation of the HHDP unit (8).   
Type IV: Oxidation of DHHPD to further oxidized subunits (9).   
In addition, due to structural differences beyond oxidation, Okuda’s classification 
system was quickly amended to include a fifth class: 
Type II-IV (+):  The roman numeral classifies the oxidation state of the gallic acids 
and a (+) indicates if any additional chemical transformations in the molecule have taken 
place (10 and 11).  
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Figure 1.  Structures of type I (6, depside bond in blue), type II tellimagrandin I (7, HHDP in red), type 
III geraniin (8, DHHDP in green), type IV phyllanthusiin A (9, DHHDP oxidation in purple), type II+ 
stachyurin (10), and type III+ mallotusinic acid (11).     
 
The presence of the HHDP or further oxidized subunits have a dramatic effect on the 
molecular recognition differences between gallotannins and ellagitannins.12  Gallotannins 
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are flexible and can orient to many conformations to adapt to their surroundings,13 whereas 
ellagitannins are rigid and have well defined three-dimensional structures.14  The 
organization of ellagitannins is believed to aid precise recognition and facilitate H-bonding 
and hydrophobic bonding to target proteins.8  Ellagitannins biological profile includes 
anticancer, antiviral and RNase H activity, whereas gallotannins have a more limited 
profile.8,15  Unfortunately, because ellagitannins are difficult to isolate from nature, synthetic 
efforts are required to further explore the biological activity of these compounds.16  
Difficulties in controlling the regio- and stereochemistry of appended gallic acids make these 
complex molecules synthetically challenging.  Moreover, controlling the atropisomers of the 
HHDP is vital to any synthetic effort on these molecules.8   
 Early synthetic efforts on ellagitannis were pioneered by Feldman and co-workers.  
Their synthesis of tellimagrandin I (7) started with the acylation of diol 11 with 3,4,5-O-benzyl  
 
Scheme 3. Synthesis of tellmagrandin I (7). Ar = 3,4,5-O-benzylgalloyl 
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protected acid 12 (Scheme 3).17  Deprotection of the benzylidene with iodine afforded diol 13. 
This compound was coupled with benzoic acid 14 via a Steglich esterificaiton, which after 
silyl ether deprotection with TBAF gave intermediate 16.  Lead tetraaceteate (Pb(OAc)4) was 
their optimal oxidizing agent to give a mixture of diastereomeric HHDP compounds 17.  The 
diastereomers were formed from different diphenyl ketal regioisomers, but this 
regiomisomeric mixture was later resolved after deprotection.  In addition, 17 was formed as 
the S atropisomer only, which is the proper orientation of the natural product.  This result is 
consistent with the Schmidt-Haslam postulate that either the S or the R conformer is 
energetically favored depending on the natural product.4,11  Okuda type II ellagitannins are 
almost always the S orientation in nature.18  Hydrogenolysis of 17 deprotected the benzyl 
groups to yield tellmagrandin I (7) in 82% yield.  Feldman’s group used similar lead 
tetraacetate strategies toward the synthesis of tellimagrandin II,19 dimeric coriariin A20 and 
sanguiin H-5.21               
 
Scheme 4. Synthesis of corilagin (22). 
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An alternative oxidative coupling strategy was developed by Yamada and co-workers 
toward the synthesis of corilagin (22, Scheme 4).22  Instead of using the diphenyl ketal group 
of acid 14, they synthesized the 4-O-benzylgallic acid derivative 19.  This acid was attached 
to diol 18 under standard Steglich esterification conditions.  After MOM-ether deprotection 
with HCl at 40 °C, compound 20 was formed in 86% yield.  The gallic acid moieties were 
oxidatively coupled with a CuCl2·BuNH2 complex to form 3,6-HHDP bridged compound 21 
as the R atropisomer only, which is consistent with atropisomeric formation of the HHDP at 
the 3,6-position.  This intermediate was used to complete the synthesis of 22.  Interestingly, 
the rigidity of the HHDP moiety at the 3,6-positions made the glucose core adopt an all axial 
orientation, and this served as the only known synthesis of an all axial oriented glucose 
natural product. 
 
Scheme 5. Synthesis of sanguiin H-5 (27).  
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Spring and co-workers developed a strategy to synthesize the key biaryl bond of 
sanguiin H-5 (27, Scheme 5) with the aid of aryl halides, which limited the protection and 
deprotection steps of the two previous strategies.  Diol 23 was esterified with halogenated 
gallic acids 24a and 24b under Steglich esterification reaction conditions.23  The halogens 
underwent metal-halogen exchange, transmetallation with CuBr·SMe2 and organocuprate 
oxidation to form compound 26 in the S configuration.  Compound 26 was deprotected to 
give the natural product 27.  
A non-biomimetic pathway was accomplished by Khanbabaee and co-workers 
towards the synthesis of strictinin (33).  They utilized a previously synthesized perbenzylated 
HHDP unit 29 to significantly shorten their synthetic route (Scheme 6).24  Diacid 29 was 
coupled to diol 28 to make 4,6-HHDP compound 30.  Unfortunately, this reaction gave a 
 
Scheme 6. Synthesis of strictinin (33). 
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mixture of atropisomers that needed to be separated by column chromatography.  The S 
configuration was isolated, and under light irradiation, the ortho-nitrobenzyl ether was 
removed.  The resulting alcohol was acylated by the addition of 3,4,5-O-benzylgallic acid 
chloride (31) to give protected intermediate 32.  Global deprotection with hydrogenolysis 
gave strictinin (33).  Although this route was more direct than the biomimetric pathways, the 
formation of atropisomers led to a poor overall yield of 12% from diol 28. 
Results and Discussion: 
We were intrigued by the complexity of these molecules and their close resemblance 
to 1,3,4,5-tetragalloylapiitol.25  Our plan was to synthesize the ellagitannins in a biomimetic 
process with minimal use of protecting groups.  Our initial effort started by coupling 
previously prepared 3,4,5-(tribenzyloxy)benzoic acid (Chapter 1) to methyl-α-D-gluco- 
pyranoside (34, Scheme 7).  Hydrogenonlysis cleaved the benzyl ethers to give tetragallate  
 
Scheme 7.  Attempts at oxidative of coupling to form compound 37. Ar = 3,4,5-O-benzylgalloyl 
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36.  Unfortunately, attempts to generate the HHDP-containing molecule, 37, using 
Feldman’s conditions with Pb(OAc)4 were unsuccessful.  Alternative oxidative methods 
using CuCl(OH)·TMEDA,26  AIBN27 and DDQ28 also failed. 
We decided that trying to form two HHDP groups at the same time might be forming too 
many side reactions, so we focused on protecting the 4,6-positions and attempt the 
oxidative HHDP coupling at the 2,3-positions.  The dimethyl ketal of 34 was formed with 2,2-
dimethoxypropane (39) and catalytic amount of para-toluenesulfonic acid (PTSA) at 60 °C 
(Scheme 8).  Acid 12 was coupled to the remaining diol 40 to give intermediate 41, which 
was subsequently deprotected to give HHDP precursor 42.  Once again, attempts to form 
the HHDP moiety with Pb(OAc)4 failed.  Different oxidation conditions known for phenol 
biphenyl couplings were attempted, including CuSO4 in O2,
29 FeCl3·6H2O,
30 K3[Fe(CN)6],
31 
CuCl2·BuNH2,
22 and VO(acac)2,
32 but none of these conditions showed any promise of 
affording the desired product 43. 
 
Scheme 8.  Attempts at oxidation of compound 42. Ar = 3,4,5-O-benzylgalloyl 
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After reexamining Feldman and Yamada’s strategies we concluded that protection of 
the para-phenol of the gallic acid is paramount to the success of these oxidative couplings.  
We decided to synthesize acid 19 and pursue Yamada’s conditions for oxidative coupling 
due to copper’s low toxicity and the regiochemical control of this reaction.  The synthesis of 
acid 19 began with the construction of the triacetate of gallic acid methyl ester (44, Scheme 
9).  Selective protection of the para-phenol was accomplished with benzyl chloride, 
potassium carbonate, and potassium iodide in refluxing acetone.33  Interestingly, compound 
44 cannot be selectively protected with these same conditions.  We believe selective 
protection at the para-position of compound 46 is preferential due to the para-acetate having 
to orient itself out of the plane making it more susceptible to deprotection.  The acetates 
were removed to give dihydroxy compound 47. Free hydroxys were subsequently 
protectedas methoxymethyl (MOM)-ethers to give compound 48.  The methyl ester was 
hydrolyzed and acidified to give acid 19.   
 
Scheme 9.  Synthesis of acid 19. 
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Due to the steric challenges of HHDP formation at the 2,3-positions of the glucose 
core, we decided to focus on its formation at the 4,6-position of glucose.21  The benzylidene 
was formed on compound 38 with benzaldehyde dimethyl acetal (49) and catalytic 
camphorsulfonic acid (CSA, Scheme 10).  Diol 50 was protected as benzyl ethers to give 
compound 51 in 84% yield.   
 
Scheme 10.  Synthesis of intermediate 51.  
 
The benzylidene was removed in an 80% acetic acid solution in water at 80 °C to 
give diol 52, which was esterified with acid 19 under Steglich esterification conditions to give  
 
Scheme 11.  Synthesis of ellagitannin 56 via Yamada’s oxidative coupling conditions. 
34 
 
diester 53 (Scheme 11).  The coupling precursor 54 was made from MOM deprotection with 
HCl at 45 °C.  Gratifyingly the key oxidative coupling with CuCl2·BuNH2 was successful at 
generating the desired product 55.  The compound was afforded as a single product and 
was easily distinguishable based on its identifiable upfield singlets at δ 6.46 and 6.84 in the 
1HNMR.  After hydrogenolysis, ellagitannin 56 was collected in 62% yield in two steps from 
compound 54.  
With the successful synthesis of ellagitannin 56, we were interested in using this 
synthetic scheme to make a variety of ellagitannins derivatives with substitutents at the C-1, 
C-2 and C-3 positions of the glucose core.  Our targets included the deprotected anomeric 
compound 56b, strictinin (33a and 33b) and ellagitannin 56c (Figure 2).  Initially we had 
hoped to hydrolyze the methyl ether of compound 56 to generate 56b, however, these 
attempts were unsuccessful with a variety of different reagents, including AcOH/1M H2SO4 
at 110 °C,34 Ac2O/AcOH, H2SO4 then N2H2·AcOH 50 °C.
35  The reactions returned starting 
material, or upon more vigorous conditions, cleaved the HHDP moiety. 
 
Figure 2.  Ellagitannin 56b, 33a, 33b, and 56c which posses the 4,6-HDDP and differing substituents 
at C-1, C-2 and C-3 of the glucose core. 
 
It was postulated that a more labile group would have to be introduced at the 
anomeric position from the beginning of the synthesis.  Accordingly, we sought to replace 
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the methoxy group with a benzyl ether.  Starting with α,β-D-glucose pentaacetate (57), 
bromo substitution at the anomeric position with HBr in AcOH, followed by nucleophilic 
displacement with benzyl alcohol afforded β-compound 58 (Scheme 12).36  The acetate 
groups were deprotected with sodium methoxide to give tetraol 59, which upon treatment 
with 49 was converted to compound 60.  The hydroxyl groups were protected as benzyl 
ethers under standard conditions of sodium hydride and benzyl bromide to yield 51b in 62% 
yield.   
 
Scheme 12.  Synthesis of diol 51b. 
 
Next, we targeted the derivate with a galloyl group at the anomeric position.  Starting 
with allyl gluco-pyranoside 61, benzylidene 64 was synthesized using 49 and catalytic 
amounts of CSA (Scheme 13).  Protection of the remaining alcohols as benzyl ethers 
afforded dibenzyl protected 63.  The O-allyl group was removed under stoichiometric PdCl2 
and sodium acetate in acetic acid.  An alternative condition with t-BuOK was attempted but 
that procedure led to the removal of the benzylidene protecting group.  The hydroxy group 
on compound 64 was esterified with acid 12 to give a mixture of α,β-diastereomers 51c and 
51d.  The two diastereomers were separated by column chromatography to yield pure 51c 
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and 51d.  Lower yields are due to the difficulty in separating the diastereomers via flash 
chromatography. 
  
Scheme 13. Synthesis of benzylidene 51c and 51d. 
 
Our next target, compound 51e, had galloyl substituents at the C-2 and C-3 positions.  
Starting with previously prepared compound 50, we made the diester under Steglich 
esterification conditions with acid 12 to give intermediate 51e (Scheme 14). 
 
Scheme 14.  Esterificaiton of compound 50 to yield benzylidene 51e. Ar = 3,4,5-O-benzylgalloyl 
 
After isolating compounds 51b-e, we turned our attention toward the installation of 
the HHDP moiety following the pathway described previously for 56a (Scheme 15).  
Benzylidene deprotection with acetic acid at 80 °C proceeded smoothly for 51b, but 
compounds 51c-e required addition of dichloroethane as a cosolvent due to starting material 
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insolubility.  Diols 52b-e were coupled to compound 19 to form products 53b-e.  Then, the 
oxidative coupling precursors 54b-e were generated from deprotection of the MOM-ethers 
with HCl without incident.  Oxidative coupling using Yamada’s conditions was effective for 
54b, but compounds 54c-e were insoluble in the reaction solvent, methanol, and attempts to 
increase solubility with heating to 40 °C led to decomposition of the starting material.   
 
SM R R1 
Yield 
(%) 51 
Yield 
(%) 52 
Yield 
(%) 53 
Yield 
(%) 54 
Pdt. R2 R3 
51a OBn α-OMe 78 85 68 62 56a OH α-OMe 
51b OBn β-OBn 76 60 75 44 56b OH α/ β-OH 
51c OBn β-OTBG 70 77 85 52 33a OH β-galloyl 
51d OBn α-OTBG 73 73 75 64 33b OH α-galloyl 
51e O-galloyl α-OMe 85 81 70 40 56c O-galloyl α-OMe 
 
Scheme 15.  Synthesis of ellagitannins 56a-c, 33a and 33b. OTBG = 3,4,5-O-benzylgalloyl 
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However, addition of dichloromethane as a co-solvent circumvented this problem and 
afforded the oxidative coupling products 55c-e in good yields.  All of the HHDP-containing 
compounds were made as a single atropisomer by this method.  The compounds were 
subjected to hydrogenolysis conditions to remove the benzyl ethers to afford ellagitannis 
56b, 56c, 33a and 33b. 
So far, we have only synthesized ellagitannins with a cyclic glucose core, but we 
wanted to extend our testing to acyclic sugars, in particular, our previously synthesized 
apiitol.  Starting with the partially protected apiitol 65 (Chapter 1), coupling with acid 19 
afforded diester 66 (Scheme 16).  The silyl ethers were deprotected to give triol 67 with no 
observed decomposition of the MOM-ethers.  Acid 12 was attached via the Steglich 
esterification to give tetragallate 68.   
 
Scheme 16. Synthesis of tetragallate 68. Ar = 3,4,5-O-benzylgalloyl  
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Deprotection of the MOM groups with HCl was successful in affording compound 69 
without eliminating the tertiary alcohol (Scheme 17).  We believe that intramolecular 
hydrogen bonding between the tertiary alcohol and carbonyl moieties stabilizes the tertiary 
alcohol with respect to elimination.  Compound 69 was oxidatively coupled with 
CuCl2·BuNH2 to give the HHDP apiitol 70 as a single atropisomer in 58% yield. Global 
deprotection with Pd(OH)2/C under a hydrogen atmosphere gave us ellagitannin 71.  
Biological testing with this compound is currently underway. 
 
Scheme 17.  Completion of the synthesis of apiitol ellagitannin 71. Ar = 3,4,5-O-benzylgalloyl 
 
So far, efforts toward the synthesis of ellagitannins have only reached the tip of the 
iceberg.  The structural diversity and recently discovered biological activity of these 
compounds will continue to inspire many new syntheses in the future.  Our work has 
demonstrated the importance of the protection of the para-phenol of gallic acid for oxidative 
coupling.  In addition, our collaborators demonstrated that many of these compounds exhibit 
40 
 
significant anti-HIV activity.  Future work on this project will focus on the synthesis of more 
derivatives, including type III and IV ellagitannins, to gain an insight into the origin of their 
anti-HIV activity.   
Experimental: 
 
Steglich esterification: 
In a round bottom flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (3 
equiv), N,N-4-dimethylaminopyridine (3.5 equiv), and acid (1.25 equiv) were added to the 
alcohol in methylene chloride.  The reaction was stirred at rt for 3 h.  When the reaction was 
complete 1 M phosphoric acid was added and the organic layer was extracted with 
methylene chloride.  The organic layer was washed with 1 M phosphoric acid, water and 
brine, dried over MgSO4, filtered and evaporated in vacuo.  The crude product was then 
purified by column chromatography.  
Benzylidene deprotection: 
In a round bottom flask, the benzylidene compound was heated in 80% acetic acid to 80 °C 
for 2 h. (Dichloroethane was added if the compound was insoluble at 80 °C.)  Upon 
completion the reaction was evaporated in vacuo. The crude material was taken up in 
EtOAc, washed with NaHCO3 (sat.) until neutral pH, water and brine, dried over MgSO4, 
filtered and evaporated in vacuo.  The crude product was purified by column 
chromatography.   
MOM deprotection: 
To a stirred solution of methoxymethyl-protected phenol in 2-propanol (80% volume) and 
THF (20% volume), was added conc. HCl (0.01 M).  The mixture was stirred for 12 h at 
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45 °C.  Sat. NaHCO3 was added until the reaction reached neutral pH.  Evaporated in vacuo.  
The mixture was extracted with ethyl acetate, washed with water and brine, dried over 
MgSO4, filtered and evaporated in vacuo.  The crude product was then purified by column 
chromatography. 
Oxidative copper coupling: 
To a stirred solution of CuCl2 (5 equiv) in methanol was added n-butylamine (20 equiv) at rt.  
The mixture was stirred for 30 min at this temperature.  The phenol in methanol (unless 
insoluble then CH2Cl2) was added and the reaction mixture was stirred at rt for 20 min.  The 
reaction was quenched with  4 M HCl and extracted with ethyl acetate.  Washed with 1 M 
HCl, sat. NaHCO3, and then brine, dried over MgSO4, filtered and evaporated in vacuo.  The 
crude product was then purified by column chromatography. 
Hydrogenolysis: 
To a stirred solution of 1 in methanol and THF was added 10% Pd(OH)2/C (10% by weight).  
The flask was evacuated and filled with H2, this process was repeated three times.  The 
reaction was stirred under a H2 atmosphere for 6 h.  Upon competition, the reaction mixture 
was filtered through a pad of celite and evaporated in vacuo to furnish the desired product.   
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(2S,3R,4S,5R,6R)-2-methoxy-6-(((3,4,5-tris(benzyloxy)benzoyl)oxy)methyl)tetrahydro-
2H-pyran-3,4,5-triyl tris(3,4,5-tris(benzyloxy)benzoate) (35). 1H NMR (300 MHz, CDCl3) δ  
3.59 (s, 3 H), 4.13 (br, 1 H), 4.49 (t, J = 12.9 Hz, 2 H), 4.90-5.21 (m, 24 H), 5.42 (t, 3 Hz, 1 
H), 5.77 (dt, J = 9.6 Hz, 3.3 Hz, 1 H), 6.07 (d, J = 6.6 Hz, 1 H), 6.27 (dt, J = 10.2 Hz, J = 3.3 
Hz 1 H), 6.96-7.52 (m, 68 H). 
 
(2S,3R,4S,5R,6R)-2-methoxy-6-(((3,4,5-trihydroxybenzoyl)oxy)methyl)tetrahydro-2H-
pyran-3,4,5-triyl tris(3,4,5-trihydroxybenzoate) (36). 1H NMR (300 MHz, COCD6) δ  3.50 
(s, 3 H), 4.21 (br, 1 H), 4.37 (m, 2 H), 4.50 (d, J = 12.9 Hz, 1 H), 5.20 (m, 1 H), 5.55 (t, J = 
9.3 Hz, 1 H), 6.02 (t, J = 9.6 Hz, 1 H), 6.70 (s, 2 H), 7.00 (s, 2 H), 7.07 (s, 2 H), 7.21 (s, 2 H) 
 
(4aR,6S,7R,8S,8aR)-6-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-7,8-
diyl bis(3,4,5-tris(benzyloxy)benzoate) (41). 1H NMR (300 MHz, CDCl3) δ  1.40 (s, 3 H), 
1.50 (s, 3 H), 3.43 (s, 3 H), 3.86-4.00 (m, 4 H), 3.89 (m, 13 H), 5.21 (d, J = 3.0 Hz, 1 H), 5.85 
(t, J = 10.2 Hz, 1 H), 7.18-7.45 (m, 34 H).  
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(4aR,6S,7R,8S,8aR)-6-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-7,8-
diyl bis(3,4,5-trihydroxybenzoate) (42). 1H NMR (300 MHz, COCD6) δ  1.29 (s, 3 H), 1.51 
(s, 3 H), 3.40 (s, 3 H), 3.63 (t, J = 6.6 Hz, 1 H), 3.73-3.90 (m, 3 H), 5.05-5.11 (m, 2 H), 5.69 
(t, J = 9.6 H, 1 H), 7.04 (s, 2 H), 7.07 (s, 2 H).  
 
(2R,3R,4S,5R,6S)-4,5-bis(benzyloxy)-2-(((4-(benzyloxy)-3,5-bis(methoxymethoxy) 
benzoyl)oxy)methyl)-6-methoxytetrahydro-2H-pyran-3-yl4-(benzyloxy)-3,5-bis 
(methoxymethoxy)benzoate (53). 1H NMR (300 MHz, CDCl3) δ  3.46 (s, 9 H), 3.47 (s, 6 H), 
3.66 (dd, J = 9.3 Hz, J = 3.6 Hz, 1 H), 4.07-4.31 (m, 4 H), 4.46 (d, 11.7 Hz, 1 H), 4.67 (m, 3 
H), 4.83 (d, J = 8.1 Hz, 1 H), 4.87 (d, J = 7.5 Hz, 1 H), 5.13-5.27 (m, 14 H), 7.13-7.53 (m, 22 
H) 13C NMR (75 MHz, CDCl3) δ 56.37, 56.30(4), 63.64, 67.75, 71.27, 73.48, 75.14, 75.19, 
75.51, 79.20, 79.57, 95.41(4), 98.04, 112.1(4), 122.2(2), 124.9, 125.2, 127.4-128.5(20), 
137.2, 137.3, 138.0, 138.2, 150.9(4), 164.7, 164.5.  
44 
 
 
(2R,3R,4S,5R,6S)-4,5-bis(benzyloxy)-2-(((4-(benzyloxy)-3,5-dihydroxybenzoyl)oxy) 
methyl)-6-methoxytetrahydro-2H-pyran-3-yl 4-(benzyloxy)-3,5-dihydroxybenzoate (54). 
1H NMR (300 MHz, CDCl3) δ  3.42 (s, 3 H), 3.70 (dd, J = 6.3 Hz, 3.6 Hz, 1 H), 4.06 (m, 2 H), 
4.30 (d, J = 7.5 Hz, 1 H), 4.54 (dd, J = 9.3 Hz, J = 3.0 Hz, 1 H), 4.60-4.67 (m, 3 H), 4.79 (d, J 
= = 5.4 Hz, 1 H), 4.82 (d, J = 5.4 Hz, 1 H), 5.10 (d, J = 8.1 Hz, 4 H), 5.29 (t, J = 7.5 Hz, 1 H), 
6.08 (br, 4 H), 7.05-7.36 (m, 24 H) 13C NMR (75 MHz, CDCl3) δ 55.65, 60.82, 63.21, 67.64, 
71.02, 73.86, 75.23, 75.29, 75.59, 79.03, 79.91, 99.39, 110.1(4), 124.7, 125.0, 127.6-
128.9(20), 136.8(2), 138.0(3), 149.2(4), 165.7, 166.6. 
 
(11aR,13S,14R,15S,15aR)-3,6,14,15-tetrakis(benzyloxy)-2,4,5,7-tetrahydroxy-13-
methoxy-11,11a,13,14,15,15a-hexahydrodibenzo[g,i]pyrano[3,2-b][1,5]dioxacyclo 
undecine-9,17-dione (55). 1H NMR (300 MHz, CDCl3) δ  3.37 (s, 3 H), 3.59 (dd, J = 9.6 Hz, 
J = 3.6 Hz, 1 H), 3.80 (d, J = 12.6 Hz, 1 H), 3.96 (t, J = 9.3 Hz, 1 H), 4.52 (d, J = 3.9 Hz, 1 H), 
4.62 (d, J = 12.0 Hz, 1 H), 4.72 (d, J = 11.4 Hz, 1 H), 4.79 (d, J = 12.0 Hz, 1 H), 4.84 (d, J = 
11.4 Hz, 1 H), 4.95 (t, J = 9.9 Hz, 1 H), 5.07-5.20 (m, 6 H), 5.61 (br, 1 H), 5.72 (br, 1 H), 5.77 
(br, 2 H), 6.46 (s, 1 H), 6.68 (s, 1 H), 7.25-7.41 (m, 20 H) 13C NMR (75 MHz, CDCl3) δ 55.61, 
63.88, 66.79, 72.27, 73.94, 75.12, 75.50, 75.65, 79.36, 79.94, 98.87, 108.1, 108.6, 113.5, 
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114.7, 127.8-129.0(20), 129.9, 130.4, 135.9, 136.1, 136.7, 136.8, 138.0, 138.4, 147.4(2), 
149.1, 149.2, 167.1, 168.2.  
 
(11aR,13S,14R,15R,15aS)-2,3,4,5,6,7,14,15-octahydroxy-13-methoxy-11,11a,13,14, 
15,15a-hexahydrodibenzo[g,i]pyrano[3,2-b][1,5]dioxacycloundecine-9,17-dione(56). 1H 
NMR (300 MHz, COCD6) δ  3.38 (s, 3 H), 3.55 (dd, J = 9.9 Hz, J = 3.3 Hz, 1 H), 3.72-3.82 
(m, 2 H), 3.94 (s, 1 H), 4.13 (dd, J = 10.5 Hz, J = 7.2 Hz, 1 H), 4.70-4.80 (m, 2 H), 5.14 (dd, 
J = 12.9 Hz, J = 6.3 Hz, 1 H), 6.59 (s, 1 H), 6.59 (s, 1 H).  
 
(2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-(((4-(benzyloxy)-3,5-bis(methoxymethoxy) 
benzoyl)oxy)methyl)tetrahydro-2H-pyran-3-yl4-(benzyloxy)-3,5-bis(methoxymethoxy) 
benzoate (53b). 1H NMR (300 MHz, CDCl3) δ  3.45 (s, 12 H), 3.64 (t, J = 9.0 Hz, 1 H), 3.78 
(t, J = 9.3 Hz, 1 H), 3, 87 (t, J = 6.9 Hz, 1 H), 4.29 (dd, J = 12.3 Hz, J = 7.2 Hz, 1 H), 4.57-
4.80 (m, 6 H), 4.93-4.98 (m, 2 H), 5.12-5.18 (m, 12 H), 5.28 (t, J = 9.9, 1 H), 7.08-7.56 (m, 
29 H) 13C NMR (75 MHz, CDCl3) δ 56.51(4), 63.97, 71.07, 71.60, 72.25, 75.04, 75.34, 
75.37(2), 81.75, 82.10, 95.61(4), 102.1, 112.4(4), 125.0, 125.5, 127.6-128.7(25), 137.1, 
137.4, 138.1, 138.4(2), 143.3, 143.4, 151.0(2), 151.1(2), 164.8, 165.7.  
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(2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-(((4-(benzyloxy)-3,5-dihydroxybenzoyl)oxy) 
methyl)tetrahydro-2H-pyran-3-yl4-(benzyloxy)-3,5-dihydroxybenzoate (54b). 1H NMR 
(300 MHz, CDCl3) δ  3.51-3.80 (m, 3 H), 4.50 (t, J = 4.8 Hz, 1 H), 4.57-4.78 (m, 6 H), 4.95-
5.00 (m, 2 H), 5.12-5.14 (d, 4 H), 5.39 (t, 9.3 Hz, 1 H), 6.23 (br, 4 H), 7.07-7.38 (m, 29 H) 13C 
NMR (75 MHz, CDCl3) δ 63.42, 71.36, 71.43, 71.76, 75.20, 75.35(2), 75.56, 81.39, 82.24, 
102.5, 110.1(4), 124.7, 125.0, 127.8-129.0(25), 136.8, 136.9, 137.1, 137.8, 137.9, 138.0, 
138.3, 149.2(4), 165.8, 166.6. 
 
(11aR,13R,14R,15S,15aR)-3,6,13,14,15-pentakis(benzyloxy)-2,4,5,7-tetrahydroxy-
11,11a,13,14,15,15a-hexahydrodibenzo[g,i]pyrano[3,2-b][1,5]dioxacycloundecine-9,17-
dione(55b). 1H NMR (300 MHz, CDCl3) δ  3.47-3.78 (m, 3 H), 3.98 (d, J = 12.9 Hz, 1 H), 
4.55-5.00 (m, 8 H), 5.09-5.23 (m, 5 H), 5.84-6.19 (br, 4 H), 6.50 (s, 1 H), 6.68 (s, 1 H), 7.17-
7.39 (m, 25 H) 13C NMR (75 MHz, CDCl3) δ 63.83, 71.43, 71.64, 72.12, 74.91, 75.38, 75.67, 
75.84, 81.35, 82.53, 103.2, 108.0, 108.8, 110.1, 113.2, 114.7, 127.9-129.1(25), 129.9, 130.6, 
135.8, 136.1, 136.7, 137.2, 138.2(2), 147.3, 147.4, 149.2(2), 167.0, 168.0. 
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(11aR,14R,15R,15aS)-2,3,4,5,6,7,13,14,15-nonahydroxy-11,11a,13,14,15,15a-hexahydro 
dibenzo[g,i]pyrano[3,2-b][1,5]dioxacycloundecine-9,17-dione (56b). 1H NMR (300 MHz, 
CDCl3) mixture of anomers 3:2 δ  3.41-3.94 (m, 4 H), 4.29-4.58 (m, 1 H), 4.82-4.85 (m, 1 H), 
5.10-5.23 (m, 1 H), 6.56 (s, 0.6 H), 6.59 (s, 0.4 H), 6.67 (s, 0.6 H), 6.68 (s, 0.4 H).   
 
(2R,4aR,6S,7R,8S,8aR)-7,8-bis(benzyloxy)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-
6-yl 3,4,5-tris(benzyloxy)benzoate1H (51c). NMR (300 MHz, CDCl3) δ  3.66 (m, 5 H), 4.41 
(dd, J = 9.9 Hz, J = 4.8 Hz, 1 H), 4.63 (d, J = 11.1 Hz, 1 H), 4.76 (d, J = 11.4 Hz, 1 H), 4.80 
(d, J = 11.4 Hz, 1 H), 4.98 (d, J = 11.1 Hz, 1 H), 5.07 (m, 2 H), 5.11 (d, J = 4.5 Hz, 2 H), 5.17 
(s, 2 H), 5.60 (s, 1 H), 5.96 (d, J = 7.8 Hz, 1 H), 7.17-7.53 (m, 32 H) 13C NMR (75 MHz, 
CDCl3) δ 66.85, 68.72, 71.36(2), 75.26(2), 75.45, 80.80, 81.27, 81.46, 94.89, 101.4, 
109.7(2), 124.0, 126.2(2), 129.2-127.5(28), 136.7(2), 137.3, 137.4, 137.8, 138.4, 143.2, 
152.7(2), 164.3. m/z: 893 [M+Na]+, 608, 568, 489; HRMS: calcd. for C55H50NaO10: 893.3296 
[M+Na]+; found 893.3279. 
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(2S,3R,4S,5R,6R)-3,4-bis(benzyloxy)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl 3,4,5-tris(benzyloxy)benzoate (52c). 1H NMR (300 MHz, CDCl3) δ  3.92-3.53 
(m, 6 H), 4.67 (d, J = 2.4 Hz, 2 H), 4.73 (d, J = 11.4 Hz, 1 H), 4.98 (d, J = 11.7 Hz, 1 H), 
5.16-5.08 (m, 6 H), 5.89 (d, J = J = 7.8 Hz, 1 H), 7.19-7.42 (m, 27 H) 13C NMR (75 MHz, 
CDCl3) δ 62.12, 70.05, 71.38(2), 75.16, 75.29, 75.54, 76.19, 81.05, 84.25, 94.94, 109.7(2), 
124.1, 128.8-127.5(25), 136.7(2), 137.4, 137.8, 138.5, 143.2, 152.8(2), 164.5. m/z: 805 
[M+Na]+, 553, 441; HRMS: calcd. for C48H46NaO10: 805.2983 [M+Na]
+; found 805.2986. 
 
(2R,3R,4S,5R,6S)-4,5-bis(benzyloxy)-2-(((4-(benzyloxy)-3,5-bis(methoxymethoxy) 
benzoyl) oxy)methyl)-6-((3,4,5-tris(benzyloxy)benzoyl)oxy)tetrahydro-2H-pyran-3-yl 4-
(benzyloxy)-3,5-bis(methoxymethoxy)benzoate (53c). 1H NMR (300 MHz, CDCl3) δ  3.45 
(s, 6 H), 3.47 (s, 6 H), 3.83 (t, J = 8.7 Hz, 1 H), 3.95 (t, J = 9.3 Hz, 1 H), 4.12 (m, 1 H), 4.25 
(dd, J = 12.6 Hz, J = 6.9 Hz, 1 H), 4.82-4.57 (m, 6 H), 5.22-5.12 (m, 17 H), 5.43 (t, J = 9.3 
Hz, 1 H), 5.99 (d, J = 7.8 Hz, 1 H), 7.13-7.51 (m, 41 H) 13C NMR (75 MHz, CDCl3) δ 56.57(4), 
63.48, 70.95, 71.38(2), 73.23, 75.19, 75.29(2), 75.37(2), 75.42, 75.47, 80.88, 81.91, 94.52, 
95.65(4), 109.7(2), 112.4(2), 112.6(2), 124.2, 124.8, 125.4, 128.7-127.6(35), 136.7(2), 137.4, 
137.5(2), 137.7, 137.8, 143.5, 150.9(2), 151.2(2), 152.8(2), 164.3, 164.8, 165.6. m/z: 1465 
[M+Na]+, 922, 859; HRMS: calcd. for C84H82NaO22: 1465.5190 [M+Na]
+; found 1465.5184.   
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(2R,3R,4S,5R,6S)-4,5-bis(benzyloxy)-2-(((4-(benzyloxy)-3,5-dihydroxybenzoyl)oxy) 
methyl)-6-((3,4,5-tris(benzyloxy)benzoyl)oxy)tetrahydro-2H-pyran-3-yl 4-(benzyloxy)-
3,5-dihydroxybenzoate (54c). 1H NMR (300 MHz, CDCl3) δ  4.05-3.87 (m, 3 H), 4.34 (d, J 
= 12.9 Hz, 1 H), 4.80-4.63 (m, 5 H), 5.20-5.10 (m, 10 H), 5.46 (t, J = 10.5 Hz, 1 H), 5.99 (d, J 
= 7.8 Hz, 1 H), 7.10-7.42 (m, 41 H) 13C NMR (75 MHz, CDCl3) δ 62.12, 70.05, 71.40(3), 
73.04, 75.25, 75.34, 75.40(2), 80.99, 81.68, 94.82, 109.7(2), 110.1(4), 123.9, 124.5, 124.9, 
130.0-127.6(35), 136.7(2), 136.9, 137.0, 137.4, 137.7(2), 138.0, 138.1, 143.3, 149.2(2), 
149.3(2), 152.8(2), 164.8, 165.8, 166.7. m/z: 1265 [M-H]+, 971, 615; HRMS: calcd. for 
C76H65O18: 1265.4176 [M-H]
+; found 1265.4149. 
 
(11aR,13S,14R,15S,15aR)-3,6,14,15-tetrakis(benzyloxy)-2,4,5,7-tetrahydroxy-9,17-
dioxo-9,11,11a,13,14,15,15a,17-octahydrodibenzo[g,i]pyrano[3,2-b][1,5]dioxacyclo 
undecin-13-yl 3,4,5-tris(benzyloxy)benzoate (55c). 1H NMR (300 MHz, CDCl3) δ  3.52 (t, 
J = 5.4 Hz, 1 H), 4.03-3.75 (m, 4 H), 4.77-4.52 (m, 4 H), 5.24-5.08 (m, 11 H), 5.91 (d, J = 7.5 
Hz, 1 H), 6.52 (s, 1 H), 6.67 (s, 1 H), 7.10-7.41 (m, 37 H) 13C NMR (75 MHz, CDCl3) δ 63.59, 
71.36, 71.48, 71.95, 72.33, 74.94, 75.23, 75.36, 75.74, 75.89, 81.35, 81.59, 94.69, 108.1, 
108.8, 109.7(2), 113.1, 114.8, 124.0, 129.1-127.6(35), 129.7, 130.8, 135.8, 136.3, 136.7, 
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136.8(3), 137.5, 137.6, 138.0, 143.2, 147.4, 147.5, 149.2, 149.3, 152.8(2), 164.5, 167.1, 
167.6. m/z: 1263 [M-H]+, 855, 529; HRMS: calcd. for C76H63O18: 1263.4020 [M-H]
+; found 
1263.3999. 
 
 
Strictinin (33a).37 m/z: 633 [M-H]+, 498, 306; HRMS: calcd. for C27H21O18: 633.0733 [M-H]
+; 
found 633.0752.   
 
(2R,4aR,6R,7R,8S,8aR)-7,8-bis(benzyloxy)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin 
-6-yl 3,4,5-tris(benzyloxy)benzoate (51d). 1H NMR (300 MHz, CDCl3) δ  3.69 (m, 5 H), 
4.03 (t, J = 9.3 Hz, 1 H), 4.75 (s, 2 H), 4.90 (d, J = 11.4 Hz, 1 H), 5.00 (d, J = 11.4 Hz, 1 H), 
5.11 (m, 2 H), 5.14 (s, 2 H), 5.17 (s, 2 H), 5.63 (s, 1 H), 6.44 (d, J = 3.9 Hz, 1 H), 7.29-7.58 
(32 H) 13C NMR (75 MHz, CDCl3) δ 65.15, 68.90, 71.43(2), 73.66, 75.24, 75.34, 78.22, 
78.38, 81.68, 91.29, 101.5, 109.8(2), 124.5, 126.2(2), 129.2-127.6(28), 136.8(2), 137.4, 
137.5, 137.8, 138.6, 143.2, 152.7(2), 164.7. m/z: 893 [M+Na]+, 589, 489, 441; HRMS: calcd. 
for C55H50NaO10: 893.3296 [M+Na]
+; found 893.3293. 
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(2R,3R,4S,5R,6R)-3,4-bis(benzyloxy)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl 3,4,5-tris(benzyloxy)benzoate (52d). 1H NMR (300 MHz, CDCl3) δ  3.83-3.69 
(m, 6 H), 4.78-4.64 (m, 3 H), 5.03 (d, J = 11.7 Hz, 1 H), 5.21-5.12 (m, 6 H) 6.49 (d, J = 3.3 
Hz, 1 H), 7.44-7.27 (m, 27 H) 13C NMR (75 MHz, CDCl3) δ 62.01, 69.58, 71.40(2), 73.00, 
73.82, 75.27, 75.35, 78.93, 80.77, 90.74, 109.7(2), 124.6, 128.8-127.5(25), 136.7(2), 137.5, 
137.6, 138.6, 143.2, 152.7(2), 164.7. m/z: 805 [M+Na]+, 553, 441; HRMS: calcd. for 
C48H46NaO10: 805.2983 [M+Na]
+; found 805.2983. 
 
(2R,3R,4S,5R,6R)-4,5-bis(benzyloxy)-2-(((4-(benzyloxy)-3,5-bis(methoxymethoxy) 
benzoyl)oxy)methyl)-6-((3,4,5-tris(benzyloxy)benzoyl)oxy)tetrahydro-2H-pyran-3-yl4-
(benzyloxy)-3,5-bis (methoxymethoxy)benzoate (53d). 1H NMR (300 MHz, CDCl3) δ  
3.41 (s, 6 H), 3.43 (s, 6 H), 3.89 (dd, J = 9.3 Hz, J = 3.6 Hz, 1 H), 4.13-4.33 (m, 3 H), 4.56 (d, 
J = 10.5 Hz, 1 H), 4.68-4.90 (m, 4 H), 5.08-5.20 (m, 18 H), 5.42 (t, J = 9.9 Hz, 1 H), 6.56 (d, 
J = 3.6 Hz, 1 H), 7.13-7.55 (m, 41 H) 13C NMR (75 MHz, CDCl3) δ 56.49(4), 63.03, 70.57, 
70.78, 71.33(2), 73.39(2), 75.34(5), 78.69, 78.97, 90.62, 95.55(2), 95.66(2), 109.7(2), 
112.3(2), 112.5(2), 124.6, 124.9, 125.3, 128.8-127.5(35), 136.8(2), 137.3, 137.5, 137.6, 
138.1, 143.1, 143.4, 150.9(2), 151.2(2), 152.6(2), 164.4, 164.8, 165.6. m/z: 1465 [M+Na]+, 
764; HRMS: calcd. for C48H46NaO10: 1465.5190 [M+Na]
+; found 1465.5190.     
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(2R,3R,4S,5R,6R)-4,5-bis(benzyloxy)-2-(((4-(benzyloxy)-3,5-dihydroxybenzoyl)oxy) 
methyl)-6-((3,4,5-tris(benzyloxy)benzoyl)oxy)tetrahydro-2H-pyran-3-yl 4-(benzyloxy)-
3,5-dihydroxybenzoate (54d). 1H NMR (300 MHz, CDCl3) δ  4.03-4.31 (m, 4 H), 4.72-4.88 
(m, 5 H), 5.16-5.32 (m, 10 H), 5.44 (t, J = 10.2, 1 H), 6.61 (d, J = 3.6 Hz, 1 H), 7.16-7.53 (41 
H) 13C NMR (75 MHz, CDCl3) δ 62.27, 69.91, 70.50, 71.46(2), 73.52, 75.08, 75.20, 75.31, 
75.42, 78.05, 78.34, 90.79, 109.8(2), 110.1(4), 124.5(2), 124.7, 130.0-127.6(35), 136.8(2), 
136.9, 137.0, 137.5, 137.7, 137.8, 138.0, 138.1, 143.2, 149.2(2), 149.3(2), 152.8(2), 164.6, 
165.9, 166.8. m/z: 1265 [M-H]+, 615; HRMS: calcd. for C76H65O18: 1265.4176 [M-H]
+; found 
1265.4155. 
 
 
(11aR,13R,14R,15S,15aR)-3,6,14,15-tetrakis(benzyloxy)-2,4,5,7-tetrahydroxy-9,17-
dioxo-9,11,11a,13,14,15,15a,17-octahydrodibenzo[g,i]pyrano[3,2-b][1,5]dioxacyclo 
undecin-13-yl 3,4,5-tris(benzyloxy)benzoate (55d). 1H NMR (300 MHz, CDCl3) δ  3.71-
4.00 (m, 5 H), 4.62-4.88 (m, 5 H), 5.00-5.24 (m, 10 H), 6.39 (d, J = 4.2 Hz, 1 H), 6.59 (s, 1 
H), 6.71 (s, 1 H), 7.25-7.43 (m, 37 H) 13C NMR (75 MHz, CDCl3) δ 63.42, 69.95, 71.36, 
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71.44(2), 73.64, 74.70, 75.40, 75.69, 75.88, 78.48, 79.29, 90.75, 107.7, 108.74, 109.8(2), 
113.1, 114.9, 124.4, 129.1-127.4(35), 129.8, 130.8, 135.7, 136.1, 136.6, 136.7, 136.8(2), 
137.5(2), 138.2, 143.1, 147.4, 147.5, 149.2, 149.4, 152.7(2), 164.4, 166.9, 167.5. m/z: 1287 
[M+Na]+, 922, 688; HRMS: calcd. for C76H64NaO18: 1287.3985 [M+Na]
+; found 1287.3996. 
 
(11aR,13R,14R,15R,15aS)-2,3,4,5,6,7,14,15-octahydroxy-9,17-dioxo-9,11,11a,13,14,15, 
15a,17-octahydrodibenzo[g,i]pyrano[3,2-b][1,5]dioxacycloundecin-13-yl3,4,5-tri 
hydroxybenzoate (33b). 1H NMR (300 MHz, COCD6) δ  3.72 (d, J = 13.2 Hz, 1 H), 3.88 (dd, 
J = 9.9 Hz, J = 4.2 Hz, 1 H), 4.08 (t, J = 9.3 Hz, 1 H), 4.41 (dd, J = 9.9 Hz, J = 6 Hz, 1 H), 
4.91 (t, J = 9.3 Hz, 1 H), 5.19 (dd, J = 13.4 Hz, J = 6.6 Hz, 1 H), 6.35 (d, J = 4.2 Hz, 1 H), 
6.60 (s, 1 H) 6.72 (s, 1 H), 7.19 (s, 2 H).  m/z: 657 [M+Na]+, 568, 454, 301; HRMS: calcd. for 
C27H22NaO18: 657.0698 [M+Na]
+; found 657.0695.   
 
(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4-diyl 
bis(3,4,5-tris(benzyloxy)benzoate) (52e). 1H NMR (300 MHz, CDCl3) δ  3.46 (s, 3 H), 3.85-
4.00 (m, 4 H), 4.94-5.04 (m, 12 H), 5.13-5.16 (m, 2 H), 5.69 (t, J = 9.9, 1 H), 7.22-7.39 (m, 
34 H) 13C NMR (75 MHz, CDCl3) δ 55.52, 62.03, 69.56, 71.10(2), 71.16(2), 71.57, 72.26, 
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74.68, 75.19(2), 97.23, 109.2(2), 109.3(2), 124.1, 124.3, 127.7-128.6(30), 136.5(2), 136.6(2), 
137.4, 137.5, 142.9, 143.0, 152.6(4), 165.8, 167.1. m/z: 1061 [M+Na]+, 715, 559; HRMS: 
calcd. for C63H58NaO14: 1061.3719 [M+Na]
+; found 1061.3709. 
 
 
(2S,3R,4S,5R,6R)-5-((4-(benzyloxy)-3,5-bis(methoxymethoxy)benzoyl)oxy)-6-(((4-
(benzyloxy)-3,5-bis(methoxymethoxy)benzoyl)oxy)methyl)-2-methoxytetrahydro-2H-
pyran-3,4-diyl-bis(3,4,5-tris(benzyloxy)benzoate) (53e). 1H NMR (300 MHz, CDCl3) δ  
3.44 (s, 6 H), 3.48 (s, 6 H), 3.53 (s, 3 H), 4.43 (m, 2 H), 4.66 (d, J = 10.5 Hz, 1 H), 4.90-5.20 
(m, 25 H), 5.32 (d, J = 3.3 Hz, 1 H), 5.63 (t, J = 9.9 Hz, 1 H), 6.13 (t, J = 9.9 Hz, 1 H), 7.19-
7.47 (m, 46 H), 7.61 (s, 2 H) 13C NMR (75 MHz, CDCl3) δ 55.66, 56.46(2), 56.53(2), 63.40, 
67.50, 69.65, 71.14(3), 71.18(2), 72.78, 75.19, 75.22, 75.33, 75.34, 95.56(2), 95.58(2), 
97.01, 109.1(2), 109.3(2), 112.4(2), 112.5(2), 124.2, 124.3, 124.4, 125.3, 127.7-128.7(40), 
136.5(2), 136.7(2), 137.4, 137.4, 137.5(2), 142.9(2), 143.3, 143.9, 151.1(4), 152.6(4), 165.0, 
165.5, 165.6, 165.7. m/z: 1721 [M+Na]+, 872; HRMS: calcd. for C99H94NaO26: 1721.5926 
[M+Na]+; found 1721.5916. 
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(2S,3R,4S,5R,6R)-5-((4-(benzyloxy)-3,5-dihydroxybenzoyl)oxy)-6-(((4-(benzyloxy)-3,5-
dihydroxybenzoyl)oxy)methyl)-2-methoxytetrahydro-2H-pyran-3,4-diyl-bis(3,4,5-
tris(benzyloxy)benzoate) (54e). 1H NMR (300 MHz, CDCl3) δ  3.51 (s, 3 H), 4.40 (br, 2 H), 
4.77-5.37 (m, 19 H), 5.65 (t, J = 9.9 Hz, 1 H), 5.87 (br, 4 H), 6.12 (t, J = 9.9 Hz, 1 H), 7.08-
7.46 (m, 48 H). 13C NMR (75 MHz, CDCl3) δ 55.91, 62.71, 67.94, 68.98, 71.16(2), 71.21(2), 
72.86, 75.18, 75.24(2), 75.28(2), 97.30, 109.0(2), 109.4(2), 110.1(4), 124.1(2), 124.2, 124.6, 
128.9-127.8(40), 136.4(2), 136.7(2), 136.8, 136.9, 137.4, 137.5, 138.1, 138.4, 142.9(2), 
149.2(4), 152.7(4), 165.7, 165.8, 165.9, 166.6. m/z: 1545 [M+Na]+, 955, 715, 489; HRMS: 
calcd. for C91H78NaO22: 1545.4877 [M+Na]
+; found 1545.4832. 
 
(11aR,13S,14R,15S,15aR)-3,6-bis(benzyloxy)-2,4,5,7-tetrahydroxy-13-methoxy-9,17-
dioxo-9,11,11a,13,14,15,15a,17-octahydrodibenzo[g,i]pyrano[3,2-b][1,5]dioxacyclo 
undecine-14,15-diyl-bis(3,4,5-tris(benzyloxy)benzoate) (55e). 1H NMR (300 MHz, CDCl3) 
δ  3.44 (s, 3 H), 3.97 (d, J=12.9 Hz, 1 H), 4.45 (br, 1 H), 4.81-5.38 (m, 20 H), 5.94 (t, J = 
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10.2 Hz, 1 H), 6.70 (s, 1 H), 6.80 (s, 1 H), 7.14-7.45 (m, 44 H). 13C NMR (75 MHz, CDCl3) δ 
55.89, 63.46, 67.78, 70.49, 71.11, 71.22(2), 71.45, 72.94, 75.18, 75.24, 75.28, 75.65(2), 
97.61, 108.2, 108.6, 109.4(4), 113.7, 114.0, 124.1, 124.2, 130.0-127.7(40), 129.7, 130.1, 
136.0, 136.1, 136.6(3), 136.7(3), 137.5, 137.6, 142.9(2), 147.3, 147.5, 149.2, 149.3, 
152.7(4), 165.7, 166.0, 167.0, 167.8. m/z: 1543 [M+Na]+, 608; HRMS: calcd. for 
C91H76NaO22: 1543.4720 [M+Na]
+; found 1545.4731. 
 
(11aR,13S,14R,15S,15aR)-2,3,4,5,6,7-hexahydroxy-13-methoxy-9,17-dioxo-9,11,11a, 
13,14,15,15a,17-octahydrodibenzo[g,i]pyrano[3,2-b][1,5]dioxacycloundecine-14,15-
diyl-bis (3,4,5-trihydroxybenzoate) (56e). 1H NMR (300 MHz, COCD6) δ  3.44 (s, 3 H), 
3.86 (d, J = 14.7 Hz, 1 H), 4.40-4.47 (br, 1 H), 5.17-5.10 (m, 3 H), 5.33 (dd, J=12.9 Hz, 6.6 
Hz, 1 H), 5.82 (t, J = 10.2 Hz, 1 H), 6.44 (s, 1 H), 6.64 (s, 1 H) 6.98 (s, 2 H), 7.05 (s, 2 H).  
m/z: 823 [M+Na]+, 552, 489, 413; HRMS: calcd. for C35H28NaO22: 823.0964 [M+Na]
+; found 
823.0952. 
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4-((tert-butyldimethylsilyl)oxy)-3-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxy 
butane-1,2-diylbis(4-(benzyloxy)-3,5-bis(methoxymethoxy)benzoate) (66). 1H NMR (300 
MHz, CDCl3) δ  0.04 (s, 3 H), 0.07 (s, 3 H), 0.10 (s, 3 H), 0.11 (s, 3 H), 0.89 (s, 9 H), 0.92 (s, 
9 H), 2.87 (br, 1 H), 3.43 (s, 6 H), 3.47 (s, 6 H), 3.61-3.80 (m, 4 H), 4.59 (dd, J = 12 Hz, J = 
9.3 Hz, 1 H), 4.72 (dd, J = 12.3 Hz, J = 2.7 Hz, 1 H), 5.10-5.21 (m, 12 H), 5.69 (dd, J = 9.0 
Hz, J = 2.1 Hz, 1 H), 7.30-7.56 (m, 14 H). 13C NMR (75 MHz, CDCl3) δ 5.48(4), 18.31(2), 
25.94(3), 25.96(3), 56.44(2), 56.46(2), 63.22, 63.35, 64.15, 73.35, 75.17, 75.28, 75.34, 
95.49(2), 95.69(2), 112.3(2), 112.5(2), 125.5, 125.7, 128.2-128.5(10), 137.4, 137.5, 143.3(2), 
150.9(2), 151.0(2), 165.2, 165.8.  . 
 
3,4-dihydroxy-3-(hydroxymethyl)butane-1,2-diylbis(4-(benzyloxy)-3,5-bis(methoxy 
methoxy)benzoate) (67). 1H NMR (300 MHz, CDCl3) δ  3.42 (s, 6 H), 3.44 (s, 6 H), 3.71-
3.89 (m, 5 H), 4.68 (dd, J = 12.0 Hz, J = 8.1 Hz, 1 H), 4.83 (dd, J = 12.3 Hz, J = 3.0 Hz, 1 H), 
5.09-5.18 (m, 12 H), 5.63 (dd, J = 8.1 Hz, J = 2.7 Hz, 1 H), 7.28-7.52 (m, 14 H).  
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2-(1,2-bis((4-(benzyloxy)-3,5-bis(methoxymethoxy)benzoyl)oxy)ethyl)-2-hydroxy 
propane-1,3-diylbis(3,4,5-tris(benzyloxy)benzoate) (68). 1H NMR (300 MHz, CDCl3) δ  
2.71 (br, 1 H), 3.37 (s, 6 H), 3.44 (s, 6 H), 4.50-4.77 (m, 5 H), 4.94-5.21 (m, 25 H), 5.94 (d, J 
= 7.2 Hz, 1 H), 7.28-7.58 (m, 48 H).  
 
2-(1,2-bis((4-(benzyloxy)-3,5-dihydroxybenzoyl)oxy)ethyl)-2-hydroxypropane-1,3-diyl 
bis(3,4,5-tris(benzyloxy)benzoate) (69). 1H NMR (300 MHz, CDCl3) δ  3.78 (br, 1 H), 4.53-
4.91 (m, 6 H), 5.06-5.13 (m, 16 H), 5.90 (br, 5 H), 7.09-7.39 (m, 48 H). 
 
2-(2,13-bis(benzyloxy)-1,3,12,14-tetrahydroxy-5,10-dioxo-5,7,8,10-tetrahydrodibenzo 
[f,h][1,4]dioxecin-7-yl)-2-hydroxypropane-1,3-diylbis(3,4,5-tris(benzyloxy)benzoate) 
(70). 1H NMR (300 MHz, CDCl3) δ  4.27 (m, 5 H), 4.69 (d, J = 11.1 Hz, 1 H), 5.06-5.14 (m, 
16 H), 5.56 (d, J = 10.5 Hz, 1 H), 6.58 (s, 1 H), 6.71 (s, 1 H), 7.15-7.38 (m, 44 H). 
59 
 
 
2-(1,2,3,12,13,14-hexahydroxy-5,10-dioxo-5,7,8,10-tetrahydrodibenzo[f,h][1,4]dioxecin-
7-yl)-2-hydroxypropane-1,3-diyl bis(3,4,5-trihydroxybenzoate) (71). 1H NMR (300 MHz, 
COCD6) δ  4.33 (dd, J = 10.8 Hz, 3.0 Hz, 1 H), 3.35-4.58 (m, 3 H), 5.13-5.18 (m, 1 H), 5.35 
(t, J = 10.5 Hz, 1 H), 5.55 (dd, J = 10.8 Hz, 3.3 Hz, 1 H), 6.54 (s, 1 H), 6.62 (s, J = 1 H), 
7.14-7.19 (m, 4 H). 
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CHAPTER 3. New approach to flavonols via base mediated cyclization 
 
Introduction: 
Flavonols are one of nine different types of flavonoids, which also include: tannins 
(Chapter 2), flavones, flavanones, isoflavones, aurones, flavanediols, anthocyanidins, 
chalcones (Figure 1).1  Flavonols are biosynthesized exclusively in plants and play an 
important role in floral pigmentation, act as signal molecules and show antimicrobial 
activity.2  Unfortunately their isolation can be problematic, as mixtures of products are 
difficult to separate.3 
 
Figure 1.  Different flavonoids structures. 
 
Flavonols are found in a variety of different foods including, tomatoes and onions4 
and have been discovered as sugar conjugates in fruits and vegetables.5  Tea and red wine 
are also known to possess a variety of different flavonols.6,7   Quercetin (1), which is found in 
red wine, has shown antiviral,8 anticancer,9 and anti-inflammatory behavior (Figure 2).10,11  
Tetramethoxy flavove 2 has shown antimicrobial, antitumor and antifungal activity.12  
Another flavonol, kaempferol (3), was reported to reduce the risk of pancreatic cancer.13  
Other flavonols have displayed antioxidant and free radical scavenging activity.14,15   
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Figure 2.  The structure of flavonol natural products Quercetin (1), 3,5,6,7-tetramethoxyflavone (2), 
and kaempferol (3). 
 
The wealth of biological activity of flavonols has attracted considerable synthetic 
attention.  The Algar-Flynn-Oyamada (AFO) reaction is the most common way to construct 
the flavonol core (Scheme 1).16,17  This reaction oxidizes chalcones 4 with hydrogen 
peroxide to the corresponding flavonol 6.  The exact mechanism of this reaction is currently 
unclear, but studies have shown that it does not go through an epoxide mechanism.18 
 
Scheme 1.  The Algar-Flynn-Oyamada (AFO) reaction. 
 
This approach has been used for the synthesis of a variety of different natural 
flavonols  One example is the synthesis of chroysosplenol D (11) from the Kraus group 
(Scheme 2).19  The synthesis commenced with an aldol condensation of acetephenone 7 
and aldehyde 5 to yield chalcone 9 in 81 % yield.  Direct oxidation to the flavonol with 
conventional AFO reaction conditions was unsuccessful, and instead, furnished the partially 
oxidized product.  This intermediate was further oxidized with iodine to afford flavonol 10 in 
47% yield over two steps.  This compound was elaborated over three steps to accomplish 
the total synthesis of 11. 
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Scheme 2. The synthesis of chroysosplenol D (11) utilizing an AFO reaction. 
 
Li and co-workers used a similar approach to synthesize a variety of different 
glycosylated flavonols 16a-g (Scheme 3).  Their synthesis began with the aldol 
condensation of 2’-hydroxyacetophenones 12a-c and benzaldehydes 13a-f to synthesize 
chalcones 14a-g.  The chalcones were oxidized with H2O2 in accordance with the AFO 
reaction conditions to provide flavonols 15a-g.  They proceeded to attach different 
monosaccharides including glucose, galactose, xylose and arabinose to their flavonols to 
generate glycosylated flavonols 16a-g.20 
Trivedi and co-workers utilized an oxidation of the 2-aryl-3-nitrochromene 17a-g to 
generate flavonols 18a-g (Scheme 4).  The nitrochromenes 17a-g were synthesized from 
the condensation of O-hydroxybenzaldehydes with substituted nitrostyrenes.   Treatment of 
17a-g with alkaline H2O2 lead to flavonols 18a-g in good yields.
21  Trivedi and co-workers 
later reported the oxidation of nitrochromenes with light irradiation and aqueous acid.22 
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# R1 R2 R3 R4 R5 
Yield 
(%) 14 
Yield 
(%) 15 
a H H OMe OMe H 50 70 
b H OMe H H H 46 74 
c H H OMe OMe OMe 35 38 
d H H H OBn H 72 71 
e OMe H OMe OMe H 30 69 
f OMe OMe OMe H H 72 62 
g OBn H H OMe H 54 76 
 
Scheme 3.  Synthesis of flavonols 15a-g. 
 
An alternative approach towards the synthesis of flavonols includes the oxidation of 
organoborane flavones to yield flavonols.23  Detty was able to synthesize flavone 21 in 63% 
yield via a coupling of 3,4,5-trimethoxyphenol (19) and phenylpropiolic acid (20) in the 
presence of Eaton’s reagent (10% P2O5 in MeSO3H, Scheme 5).  The anion was generated 
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at C-3 with LDA and quenched with trimethylborate to give organoborate 22.  This 
compound was oxidized with H2O2 in acetic acid to give flavonol 23.    
 
# R1 R2 R3 
Yield 
(%) 
a H H H 76 
b H OMe H 80 
c H Cl H 70 
d H Me H 72 
e H OMe OMe 89 
f OMe H H 79 
g OMe Me H 83 
 
Scheme 4.  Synthesis of flavonols 18a-g from 2-aryl-3-nitrochromenes 17a-g. 
 
at C-3 with LDA and quenched with trimethylborate to give organoborate 22.  This 
compound was oxidized with H2O2 in acetic acid to give flavonol 23.    
 Shaw and Urgaonkar utilized a Baker-Venkataraman-type reaction to synthesize 
flavonol 27 as a key intermediate towards their total synthesis of Kaemferitin (28), which is 
the 3,7-dirhamoniside of kaempferol (3, Scheme 6).  Intermediate 24 was made from 
phloroglucinol undergoing a Houben-Hoesch reaction, followed by selective MOM 
deprotection.24  Esterificaiton with acid 25 afforded flavonol precursor 26.  Cyclization with 
potassium carbonate in boiling pyridine was successful in generating the desired 5- 
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Scheme 5.   Synthesis of flavonol 23. 
 
hydroxyflavone 27.  It is worth mentioning that the basic conditions also cleaved the MOM-
ether ortho to the carbonyl.  In 5 more steps they were able to generate the natural product 
28.  This Baker-Venkataraman-type reaction has been used to synthesize pelargonidin 3-O-
6”-O-acetyl-β-D-glucopyranoside, a kaempferol glucoside,25 and glycosylated 1.26  
 
Scheme 6. Synthesis of Kaemferitin (28). 
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Results and Discussion: 
 While the encouraging biological profile of flavonols has inspired numerous synthetic 
efforts, many of these syntheses revolve around a late-stage oxidation of flavones.  We 
were interested in designing a direct synthesis of these molecules conceptually different 
than the previous syntheses.  Our retrosynthetic analysis focused on the disconnection 
between C-2 – C-3 of compound 30 (Scheme 7).  This key C-C bond would originate from 
intramolecular attack of the benzyl anion on the ethyl ester of the 1,2 dicarbonyl followed by 
elimination of a leaving group.  Precursor 31 could be derived from α-keto ester 32. 
 
Scheme 7. Retrosynthetic analysis of the construction of flavonols. 
 
Our synthesis began with the titanium tetrachloride (TiCl4) mediated Friedel-Crafts 
acylation of commercially available 3,4,5-trimethoxyphenol (19) with ethyl chlorooxoacetate 
(33) to give α-keto ester 34 (Scheme 8).  Due to its inherent nucleophilicity, the nitrile group 
would serve a dual role in the synthesis – it will act as an activator of benzylic position and  
leaving group.  To this end, α-bromophenylacetonitrile (34) was O-alklyated to yield benzyl 
ether 36 in 70% yield.   
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Scheme 8.  Synthesis of α-keto ester 36. 
 
With this intermediate in hand, we attempted our key base mediated cyclization to 
form the corresponding flavonols; however, instead we recovered the 5-membered 
cyclization product 37 (Scheme 9).  Attempts at converting this intermediate to flavonol 23 
with potassium hydride (KH) were unsuccessful.  Undeterred, we reduced compound 36 
with sodium borohydride (NaBH4) to a diastereomeric mixture of α-hydroxy-esters 38.  
Gratifyingly, with two equivalents of LDA and elevated temperatures we were able to 
generate flavonol 23 as a single product.  Using standard methylation reaction conditions, 
23 was methylated to yield natural product 2.27    
 
Scheme 9.  Completion of the synthesis of natural product 2. 
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The proposed mechanism of our key base-mediated cyclization step is depicted in 
Scheme 10.  The first equivalent of base deprotonates the hydroxy group while the second 
equivalent generates the benzylic anion.  This anion attacks the α-keto ester 39, which in 
turn eliminates ethoxide.  Compound 41 then tautomerizes to form intermediate 42, which 
can facilitate the elimantion of the cyanide to form the desired flavonol 23.  
 
Scheme 10.  Proposed mechanism of compound 38 to flavones 23. 
 
In order to test the scope and limitations of this reaction we decided to vary the 
substituents on the A ring of the flavonol.  We started with 4-chloropehenol (43) and reacted 
it with ethyl chlorooxoacetate (33) under Friedel-Crafts conditions, but unfortunately the O-
acylated product 44 resulted (Scheme 11).  A Fries rearrangement was attempted to 
generate the C-acylated product, however this reaction was unsuccessful. 
 
Scheme 11.  O-Acylation of 4-chlorophenol (43) with 33. 
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Alternatively, 3,5-dimethoxyphenol (19b) and 3-methoxyphenol (19c) were subjected 
to the Friedel-Crafts conditions and gave the desired C-acylated products 34b-c (Scheme 
12).  These products were taken forward to the O-alklyation step with 35 to give benzyl 
ethers 36a-c.  The yield of 36b is significantly lower than the previous reaction due to an 
unidentified side reaction, with this side-product being more pronounced at higher 
temperatures.  Reduction of the ketone with NaBH4 in ethanol yielded diastereomers that 
were taken to the cyclization step without purification.  The base-mediated cyclization step 
was successful in generating the corresponding flavonols 23a-c. 
 
# R1 R2 
Yield 
(%) 34 
Yield 
(%) 36 
Yield 
(%) 23 
a OMe OMe 80 70 51 
b H OMe 89 25* 63 
c H H 85 67* 60 
 
Scheme 12. Synthesis of flavonols 23a-c. *brsm 
 
72 
 
Our synthetic pathway provides an efficient new way to synthesize flavonols.  Further 
optimization of these reaction conditions could provide a valuable route towards these 
biologically active molecules.   
Experimental: 
Friedel-Crafts Acylation: 
To a solution of phenol 19a-c (1.0 equiv) in CH2Cl2, was added titanium tetrachloride (1.1 
equiv) at -20 °C under argon. To this dark brown solution, ethyl chlorooxoacetate (33) (1.1 
equiv) was added dropwise while maintaining temperature at or below -15 °C. The resulting 
reaction mixture was stirred for 4 h with a steady increase in temperature to 0 °C. After the 
completion of the reaction, the reaction mixture was diluted with CH2Cl2 and poured over 
cold HCl (1.0 M) solution. The aqueous layer was separated and extracted with CH2Cl2. The 
combined organic extracts were washed with HCl (1.0 M) solution and brine followed by 
drying over anhydrous MgSO4. The solvent was evaporated in vacuo to obtain the crude 
compound 34a-c. The crude compounds were then purified by silica gel column 
chromatography. 
O-alkylation: 
To a slurry of NaH (1.1 equiv) in dry DMF under argon, phenols 34a-c (1.0 equiv) was 
added at 0 °C. The resulting reaction mixture was stirred at 0 °C for 15 minutes followed by 
the addition of phenylacetonitrile 35 (1.1-1.5 equiv) at the same temperature. The reaction 
mixture was then stirred at 60 °C for 2-10 h. After the completion of the reaction, the 
reaction mixture was quenched by adding saturated NH4Cl solution. The reaction mixture 
was then extracted with EtOAc (3 x 100 ml). The combined organic extracts were then 
washed with water and brine, dried over anhydrous MgSO4, filtered and evaporated in vacuo. 
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The crude compound was purified by column chromatography to give pure 36a-c 
respectively. 
Reduction and Base-Mediated Cyclization: 
In a round bottom flask, ketone 36a-c (1.0 equiv) was suspended in anhydrous ethanol 
under inert conditions in an ice-acetone bath. To this, NaBH4 (1.1 equiv) was added and the 
reaction mixture was warmed to room temperature over 1-3 h. After the completion of 
reaction, the reaction mixture was quenched with HCl (2.0 M) solution until the gas evolution 
stopped. The mixture was then diluted with water and extracted with EtOAc (2 x 100 ml). 
The combined organic extracts were then washed with water and brine, dried over 
anhydrous MgSO4, filtered and evaporated in vacuo to obtain crude as a mixture of 
diastereomers. The crude compounds were purified by column chromatography and were 
taken to next step as diastereomeric mixtures. 
To a solution of diisopropylamine (2.3 equiv) in dry THF under argon, was added n-BuLi (2.5 
M in hexanes) (2.2 equiv) at -78 °C. The mixture was warmed to -40 °C and stirred at this 
temperature for 45 minutes.  The solution was returned to -78 °C and a solution of α-
hydroxy-ester in dry THF was added to it. The resulting reaction mixture was warmed to rt 
and then refluxed for 8 h. After the completion of the reaction, the reaction mixture was 
quenched with HCl (1.0 M) solution until acidic and then returned to neutral pH with 
saturated NaHCO3 solution.  Most of the THF was evaporated in vacuo. The residue was 
then diluted with water and extracted with EtOAc (3 x 50 ml). The combined organic extracts 
were then washed with water and brine, dried over anhydrous MgSO4, filtered and 
evaporated in vacuo. The crude compound was then purified by column chromatography. 
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Preparation of 2: 
Flavonol 15 (0.04 g, 0.12 mmol) was taken in dry acetone and anhydrous K2CO3 was added 
to it under argon. To this, methyl iodide (0.03 g, 0.18 mmol) was added and resulting 
reaction mixture was refluxed for 6 h. After the completion of reaction, the reaction mixture 
was filtered through celite and evaporated to dryness. The residue was then diluted with 
water and extracted with EtOAc (3 x 20 ml). The combined organic extracts were then 
washed with water and brine, dried over anhydrous MgSO4, filtered and evaporated in vacuo 
to obtain crude 2. The crude compound was then purified by column chromatography using 
50% EtOAc/hexanes as eluent to get pure flavonol 2 (0.03 g, 0.10 mmol) in 80 % yield. 
 
 
Ethyl 2-(6-hydroxy-2,3,4-trimethoxyphenyl)-2-oxoacetate (19a). (15% EtOAc/hexanes, 
80% yield). yellow solid, recrystalized EtOAc/hexanes, mp 50-51 °C; 1H-NMR (400MHz, 
CDCl3) δ 11.95 (s, 1H), 6.25 (s, 1H), 4.38 (q, J = 7.2 Hz, 2H), 3.91 (s, 3H), 3.91 (s, 3H), 3.77 
(s, 3H), 1.40 (t, J = 7.2 Hz, 3H); 13C-NMR (100MHz, CDCl3): δ 189.3, 164.2, 162.9, 154.2, 
134.1, 104.7, 96.0, 62.0, 61.6, 61.1, 56.5, 14.1; MS (m/z): 307 (M+Na+), 239, 211; HRMS 
calcd for C13H16O7: 284.0900, found: 284.0896. 
 
Ethyl 2-(2-hydroxy-4,6-dimethoxyphenyl)-2-oxoacetate (19b). (25% EtOAc/hexanes, 89% 
yield). orange solid, recrystalized EtOAc/hexanes, mp 52-53 °C; 1H-NMR (400MHz, CDCl3) 
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δ 12.35 (s, 1H), 6.09 (s, 1H), 5.92 (s, 1H), 4.38 (q, J = 8 Hz, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 
1.40 (t, J = 8 Hz, 3H); 13C-NMR (100MHz, CDCl3): δ 188.5, 168.9, 168.2, 164.5, 162.5, 
102.3, 94.0, 91.4, 61.9, 56.3, 56.0. 14.3; MS (m/z): 277 (M+Na+), 209, 181; HRMS calcd for 
C12H15O6: 255.0863, found: 255.0863. 
 
Ethyl 2-(2-hydroxy-4-methoxyphenyl)-2-oxoacetate (19c). (20% EtOAc/hexanes, 85% 
yield). yellow oil; 1H-NMR (300MHz, CDCl3) δ 11.76 (s, 1H), 7.66 (d, J = 9 Hz, 1H), 6.51 (d, 
J = 2.4 Hz, 1H), 6.48 (dd, J = 6 Hz, J = 2.4 Hz, 1H), 4.45 (q, J = 7.2 Hz, 2H), 3.88 (s, 3H), 
1.43 (t, J = 7.2 Hz, 3H); 13C-NMR (100MHz, CDCl3): δ 188.4, 167.8, 167.1, 162.8, 133.9, 
110.4, 109.0, 101.0, 62.6, 55.9, 14.2; MS (m/z): 247 (M+Na+), 191, 170, 151; HRMS calcd 
for C11H13O5: 225.0757, found: 225.0754. 
 
Ethyl 2-(6-(cyano(phenyl)methoxy)-2,3,4-trimethoxyphenyl)-2-oxoacetate (34a). (20% 
EtOAc/ hexanes, 70% yield). yellow oil; 1H-NMR (400MHz, CDCl3) δ 7.63 – 7.69 (m, 2H), 
7.35 – 7.50 (m, 3H), 6.62 (s, 1H), 5.96 (s, 1H), 4.21 (m, 2H), 3.91 (s, 6H), 3.83 (s, 3H), 1.31 
(t, J = 7.2 Hz, 3H); 13C-NMR (100MHz, CDCl3): δ 184.7, 163.6, 158.5, 155.0, 152.9, 138.5, 
132.5, 130.4, 129.3, 127.9, 116.9, 114.3, 100.0, 72.4, 62.4, 62.3, 61.2, 56.6, 14.2; MS (m/z): 
399 (M+), 327, 325, 283, 282, 254, 211, 210, 209; HRMS calcd for C21H21NO7: 399.1318, 
found: 399.1326 
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Ethyl 2-(2-(cyano(phenyl)methoxy)-4,6-dimethoxyphenyl)-2-oxoacetate (34b). (50% 
EtOAc/hexanes, 17% yield, 25% based on SM recovered). yellow solid, recrystalized 
EtOAc/hexanes, mp 146 °C; 1H-NMR (300MHz, CDCl3) δ 7.67-7.64 (m, 2H), 7.49-7.46 (m, 
3H), 6.41 (s, 1H), 6.28 (s, 1H), 5.95 (s, 1H), 4.18-4.13 (m, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 
1.28 (t, J = 7.5 Hz, 3H); 13C-NMR (100MHz, CDCl3): δ 184.2, 164.5, 163.9, 162.6, 158.4, 
132.1, 130.4, 129.3, 127.7, 117.5, 109.1, 95.8, 93.9, 70.4, 62.0, 56.4, 55.9, 14.2; MS (m/z): 
392 (M+Na+), 370, 276, 256, 203, 144; HRMS calcd for C20H20NO6: 370.1285, found: 
370.1279. 
 
Ethyl 2-(2-(cyano(phenyl)methoxy)-4-methoxyphenyl)-2-oxoacetate (34c). (33% 
EtOAc/hexanes, 48% yield, 76% based on SM recovered). yellow oil; 1H-NMR (300MHz, 
CDCl3) δ 7.97 (d, J = 8.7 Hz, 1H), 7.62-7.60 (m, 2H), 7.53-7.51 (m, 3H), 6.74 (dd, J = 9 Hz, J 
= 2.1 Hz 1H), 6.64 (d, J = 2.1 Hz 1H), 5.91 (s, 1H), 3.90 (s, 3 H), 3.81 (q,  J = 7.5 Hz, 2H), 
1.14 (t, J = 6.6 Hz, 3H); 13C-NMR (100MHz, CDCl3): δ 184.7, 166.4, 165.2, 158.2, 133.8, 
131.5, 130.8, 129.5, 128.1, 116.7, 115.9, 108.7, 100.5, 69.0, 61.8, 56.1, 14.0; MS (m/z): 362 
(M+Na+), 340, 266, 246; HRMS calcd for C19H17NNaO5: 362.0999, found: 362.1004. 
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3-Hydroxy-5,6,7-trimethoxy-2-phenyl-4H-chromen-4-one (23a). (40% EtOAc/hexanes, 51% 
yield). brown solid, recrystalized EtOAc/hexanes, mp 150-152 °C; 1H-NMR (400MHz, CDCl3) 
δ 8.21 (d, J = 8.6 Hz, 2H), 7.51 (t, J = 6.8 Hz, 2H), 7.44 (t, J = 7.2 Hz, 1H), 6.79 (s, 1H), 4.03 
(s, 3H), 3.98 (s, 3H), 3.92 (s, 3H); 13C-NMR (100MHz, CDCl3): δ 172.0, 158.6, 154.0, 151.9, 
142.7, 140.1, 138.3, 131.3, 130.0, 128.7, 127.5, 110.0, 96.3, 62.5, 61.8, 56.6; MS (m/z): 329 
(M+H+), 328, 326, 314, 313, 267, 167, 105, 77, 69; HRMS calcd for C18H17O6: 329.1011, 
found 329.1020. 
 
3-Hydroxy-5,7-dimethoxy-2-phenyl-4H-chromen-4-one (23b). (5% CH3OH/CH2Cl2, 63% 
yield). brown solid, recrystalized EtOAc/hexanes, mp 169-170 °C; 1H-NMR (300MHz, CDCl3) 
δ 8.23 (d, J = 9 Hz, 2H), 7.55-7.45 (m, 3H), 6.59 (d, J = 3 Hz, 1H), 6.38 (d, J = 3 Hz, 1H), 
4.00 (s, 3H), 3.93 (s, 3H); 13C-NMR (100MHz, CDCl3): δ 172.1, 164.6, 160.6, 159.0, 141.9, 
138.4, 131.1, 129.7, 128.6, 127.3, 106.2, 95.9, 92.5, 56.5, 56.0; MS (m/z): 299 (M+H+), 237, 
144; HRMS calcd for C17H15O5: 299.0914, found: 299.0919. 
 
3-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one (23c). (2% CH3OH/CH2Cl2, 60% yield). 
brown solid, recrystalized EtOAc/hexanes, mp 167-169 °C; 1H-NMR (300MHz, CDCl3) δ 
8.25 (d, J = 9 Hz, 2H), 8.16 (d, J =9 Hz, 1H), 7.57-7.47 (m, 3H), 7.03-6.98 (m, 2H), 3.95 (s, 
3H); 13C-NMR (100MHz, CDCl3): δ 173.0, 164.5, 157.6, 144.4, 138.3, 131.4, 130.1, 128.8, 
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127.7, 127.0, 115.1, 114.8, 100.1, 56.1; MS (m/z): 269 (M+H+), 239, 189, 150; HRMS calcd 
for C16H13O4: 269.0808, found: 269.0808. 
 
3,5,6,7-tetramethoxyflavone (2) yellow oil; 1H-NMR (400MHz, CDCl3) δ 8.06 (dd, J = 8.0 
Hz, J = 2.0 Hz, 2H), 7.45 – 7.53 (m, 3H), 6.75 (s, 1H), 4.00 (s, 3H), 3.96 (s, 3H), 3.91 (s, 3H), 
3.86 (s, 3H); 13C-NMR (100MHz, CDCl3): δ 174.0, 157.9, 153.9, 153.5, 152.6, 141.6, 140.4, 
131.0, 130.6, 128.7, 128.6, 128.4, 113.4, 96.3, 62.4, 61.8, 60.3, 56.5; MS (m/z): 342, 327, 
323, 297, 284, 283, 241, 195, 167, 129, 105, 88, 76, 68; HRMS calcd for C19H18O6: 
342.1103, found: 342.1108.  
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CHAPTER 4. Synthesis of azafluorenones 
 
Introduction: 
Azaflouorenones are fused tricyclic compounds that are pyridine analogs to 
fluorenones.  In 1976, researchers discovered the first azafluorenone natural product, 
onychine (1, Table 1, entry 1).1 Since then, 24 different azafluorenone natural products have 
been reported (Table 1, entry 2-25). These azafluorenones have been isolated from a 
variety of plants and are believed to derive from aporphine during their biosynthesis.2  They 
have shown a wide range of antimicrobial activity against several microorganisms including 
C. albicans, Escherichia coli and Saccharomyces cerevisiae.3,4,5  The isolated 
azafluorenones contain a methyl group at C-1, and different substituents at the R2, R5, R6, 
R7 and R8 positions thus far.      
 
Compound R2 R5 R6 R7 R8 Compound R2 R5 R6 R7 R8 
1
6
 H H H H H 14
7
 H OAc OMe OAc H 
2
8
 H H OMe H H 15
9
 H OH OMe H OH 
3
10
 H H OH H H 16
11
 H OMe OMe OH H 
4
12
 H OH OMe H H 17
11
 H OMe OMe OAc H 
5
10
 OMe H OMe OH H 18
11
 H OMe OMe OMe H 
6
10
 H OMe OMe H H 19
11
 H H H OH OMe 
7
10
 H H H H OH 20
11
 H H H OAc OMe 
8
10
 H OMe H H OMe 21
11
 H H H OMe OMe 
9
10
 H OAc OMe H H 22
13
 H OMe H H H 
10
14
 H H OH OMe H 23
13
 H H H OMe H 
11
14,15
 H H OMe OH H 24
13
 H H H H OMe 
12
14,15
 H H OMe OMe H 25
11,16
 H OMe OH H H 
13
7
 H OH OMe OH H       
 
Table 1.  The azafluorenone natural products. 
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 Currently, there are four different methods to synthesize azafluorenones: N-oxime 
rearrangements, imine condensations, Diels-Alder reactions and nucleophilic ring closures 
(Scheme 1).  Of these four methods, only N-oxime rearrangements have been widely used 
for the synthesis of a variety of the natural azafluorenones.  
 
 
Scheme 1.  Four pathways to the construction of azafluorenones. 
 
N-oxime rearrangements: 
When researchers isolated onychine they had difficulty in unambiguously assigning 
the structure between compound 26 and 1 (Figure 1).1  In order to assign the structure they 
reduced the ketone to the corresponding alcohol which resulted in only a slight high-field 
shift in the methyl protons in the 1H NMR compared to the parent compound.  This small 
shift insinuated that compound 26 was the correct structure, due to the methyl being further 
removed from the carbonyl moiety and thus having only a very slight effect on the shift of the 
methyl peak.1  However, without more advanced characterization techniques or a synthesis 
of the molecule to confirm the structure, no definitive assignment could be made.   
83 
 
 
Figure 1.  Proposed structures of onychine. 
 
Irie and co-workers were interested in using their newly developed methodology 
towards the construction of pyridine rings using oxidative thermal rearrangement of N-oxides 
to confirm the structural assignment of onychine.  Their synthesis began with reacting 2-
indanone (27) with hydroxylamines 28 and 29 to furnish the corresponding N-oximes 30 and 
31 (Scheme 2).17  Each N-oxime was independently heated in a sealed tube at 170-180 °C 
for 2 days to give the same mixture of azafluorenes 32 and 33.  The two compounds were 
then separated by preparative TLC chromatography.  Compound 32 was oxidized with 
potassium permanganate (KMnO4) to give azafluorenone 26.   
 
Scheme 2. The total synthesis of compound 26. 
 
Unfortunately, the newly synthesized product did not match the spectral data of the 
isolated compound.  Believing the initial characterization assignment was incorrect, Irie and 
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co-workers decided to synthesize 1.  Starting with 1-indanone (34), they formed N-oximes 
35 and 36, which were thermally heated to construct the requisite azafluorene mixtures of 
37 and 38 (Scheme 3).  Compound 13 was oxidized with KMnO4 to give azafluorenone 1.  
This compound compared favorably with the spectral data for the isolated onychine and the 
structure was reassigned.  Arango and co-workers later confirmed this reassignment by 
NOE experiments.11   
 
Scheme 3. The total synthesis of azafluorenone 1. 
 
This method has also proven versatile to substitutions at R5, R6 and R7, including the 
synthesis of isoursuline (4, Scheme 4).  The N-oxime 40 was made by reacting 7-hydroxy-6-
methoxyindanone (39) with crotylhydroxylamine (5).18  This oxime was heated at 170 °C for 
20 h to make compounds 41 and 42.  Compound 41 was then protected as the 
methoxymethyl (MOM) ether 43.  The benzyl position was oxidized with KMnO4 and 
deprotected under acidic conditions to furnish 17 in 75% yield over 3 steps.  Similar routes 
were used to complete the synthesis of ursuline (25),18 10,14 1114 and 12.14,19  The use of N-
oximes have proven versatile towards the synthesis of azafluorenone natural products.  
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However, their modest yields, harsh conditions and poor regioselectivity suggest better 
alternatives may be possible. 
 
 
Scheme 4.  The synthesis of isoursuline (4). 
 
Imine condensations: 
In 1949, Petrow and co-workers reported the first synthesis of an azafluorenone.20   
 
# R 
Yield 
(%) 47 
Yield 
(%) 48 
a CO2Et 100 90 
b COMe 100 100 
c COPh 20 100 
 
Scheme 5. The synthesis of azafluoreones 48a-c. 
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Their synthesis began with 2-benzylidene-1,3-indandione (45) reacting with different 
enamines (46a-c) at 100 °C to give the tricyclic structures 47a-c (Scheme 5).  These 
compounds were successfully oxidized with chromic acid to give azafluorenones 48a-c.   
In 2007, this method was modified by Tu and co-workers in a one-step three 
component reaction to make azafluorenones under microwave irradiation.21  They reacted 
benzaldehydes (49a-f), 1,3-indandione (50) and acetophenones (51a-f) in the presence of 
ammonium acetate under microwave conditions to afford azafluorenones 52a-f (Scheme 6).  
This reaction was effective with a variety of different functional groups including electron-rich, 
electron-poor and halogen substituents.   
 
# R R1 
Yield 
(%) 52 
a NO2 OMe 89 
b F OMe 80 
c OMe OMe 78 
d Cl Cl 88 
e Cl F 84 
f OMe F 83 
 
Scheme 6. The synthesis of 52a-f in a one pot three component synthesis. 
 
This methodology was further elaborated to include heteroatom substitution at C-3 and 
cyano substitution at the C-2 position (Scheme 7).  Starting with arylidenemalononitriles 
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53a-g, 50 and sulfur (54a-d) or nitrogen (54e-g), they generated azafluorenones 55a-g.22  
This synthesis allowed easy access to a variety of different derivatives; however, there was 
no direct route based on these reactions to the azafluorenone natural products with 
regiocontrol.   
 
# R X R1 
Yield 
(%) 55 
a 4-ClC6H4 SH CH2CO2H 87 
b 4-MeOC6H4 SH CH2CO2H 80 
c 4-ClC6H4 SH 4-MeC6H4 85 
d 3-NO2C6H4 SH 4-MeC6H4 88 
e 4-ClC6H4 NH2 4-MeC6H4 91 
f 4-ClC6H4 NH2 C6H5 84 
g 4-NO2C6H4 NH2 4-OHC6H4 84 
 
Scheme 7. Synthesis of 55a-g under microwave irradiation. 
 
Diels-Alder: 
The Diels-Alder reaction has also been utilized to construct azafluorenones.  In a 
synthesis of onychine (1), researchers made tricyclic 58 from the cycloaddition of indene (56)  
 
Scheme 8.  The synthesis of onychine (1) using a key Diels-Alder reaction. 
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with unsaturated imine 57 (Scheme 8).  After 4 steps they transformed intermediate 58 into 
onychine (1).23     
An alternative Diels-Alder strategy resulted in the isomeric 2-azafluorenones.  In 
three steps inverse-electron-demand Diels-Alder reaction precursors 59a-g were made 
(Scheme 9).  The intramolecular Diels-Alder reaction was heated to 100-120 °C for 1.5 h to 
generate azafluorenones 60a-g in good yields.24  This method is also amenable to the 
synthesis of 1-azafluorenones.25  While these syntheses provide an elegant use of the Diels-
Alder reaction, their lengthy synthetic precursors make the synthesis inefficient. 
 
# R1 R2 R3 R4 
Yield 
(%) 60 
a Ph H H SiMe3 88 
b Ph H H CH2OH 84 
c Ph H H CH2NMe2 76 
d Ph H H (CH2)3Me 79 
e Ph OMe OMe (CH2)3Me 78 
f Ph OCH2O CH2NMe2 57 
g 4-MeOC6H4 OMe OMe CH2NMe2 68 
 
Scheme 9.  Synthesis of azafluorenones 60a-g via an intramolecular Diels Alder reaction. 
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Nucleophilic ring closure:  
The last conceptually different strategy to synthesize azafluorenones involves 
nucleophilic attack of carbonyls to close the cyclopentanone ring.  Snieckus’ 
groupsynthesized biaryl compounds 64a-d via a Suzuki coupling (Scheme 10).  These 
intermediates were exposed to excess lithium diisopropylamide (LDA) to facilitate ring 
closure to make azafluorenones 65a-d.  The amides not only served as ortho-directing 
groups, but also as the carbonyl source of the azafluorenone.26  Snieckus’ group also 
reported a similar cross-coupling procedure toward the synthesis of onychine (1).27 
 
# X Y Z R R1 
Yield 
(%) 64 
Yield 
(%) 65 
a N C C CN H 71 55 
b C N C OMe H 71 56 
c C N C H OMe 57 63 
d C C N H Cl 61 81 
 
Scheme 10. The synthesis of azafluorenone compounds 65a-d. 
 
Mongin’s group had a similar approach; however, they had difficulty in selectivity 
generating the anion to cyclize the cyclopentanone ring.  Initial attempts of metallation at -
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78 °C of compound 67 led to deprotonation of the C-5’ position compared to C-3’ based on 
D2O quenching (Scheme 11).  When the temperature was raised to -50 °C, the compound 
cyclized to product 68 in 68% yield.28  They completed the synthesis of 1 by using a Suzuki 
coupling to install the methyl at the C-1 position.  Mechanistic studies on these systems 
have shown that selectivity of the deprotonation is dependent on if the carbonyl is an acid, 
ester or amide.29  There are also reports of Friedel-Crafts acylation to close the 
cyclopentenone.30,31     
 
 
Scheme 11.  Nucleophilic ring closure to synthesize 1.  
 
Results and Discussion: 
Our interest in azafluorenones came from a recent report on the encouraging 
antimalarial activity of isoursuline (4).  It had IC50 values of 9.9 and 11.4 μM against 3D7 and 
Dd2 strains of the malaria causing parasite Plasmodium falciparum, respectively.9  Current 
commercially available malaria drugs are rapidly losing their efficacy.32  Moreover, there is a 
constant need for the development of new antimalarial drugs to combat the emergence of 
drug-resistant strains of the disease.33  There are 600 million new malarial infections each 
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year with 1 million people dying from the disease.9  The WHO suggests the majority of new 
antimalarial drugs will come from current natural products.34  
 Currently there is one synthesis of 4;18 however, this route is plagued with the 
excessive use of protecting groups, poor yields and regioselectivity issues.  We were 
interested in improving this route and developing a more universal synthesis toward 
azafluorenone natural products.  We envisioned a one-step synthesis of 4, starting with 
commercially available 2-chloro-4-methyl pyridine (70, Scheme 12).  Deprotonation ortho to 
the activating chloride, followed by quenching with methyl benzoate 71 would give the 
corresponding ketone.  We expected this intermediate to undergo nucleophilic aromatic 
substitution to produce 4.  This method would provide an efficient route to this biologically 
active compound and access to other azafluorenone natural products. 
 
Scheme 12.  Proposed one-step synthesis of isoursuline (4). 
 
Due to the cost of 2-chloro-4-methylpyridine (70), the feasibility of this reaction was 
first tested with 2-chloropyridine (72) in a model system study (Scheme 13).  LDA 
successfully deprotonated the 3-position of the pyridine, which reacted with methyl benzoate 
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73 to generate the ketone intermediate.  However, the reaction did not continue through the 
intramolecular nucleophilic aromatic substitution reaction envisioned.35   
 
Scheme 13.  Model system study of the synthesis of 74. 
 
We decided to push the intramolecular cyclization under different reaction conditions.  
Due to the poor yield of the ketone, methyl benzoate 73 was switched to the more 
electrophilic isovanillin (77) to improve reactivity and better replicate the real system.  
Compound 72 was subjected to our previous deprotonation conditions and quenched with 
77 to yield alcohol 78 (Scheme 14).  Initial attempts to oxidize benzyl alcohol to the ketone 
with a variety of different oxidizing agents, including; pyridinium chlorochromate (PCC), 
pyridinium dichromate (PDC), Swern oxidation and manganese dioxide (MnO2), were all 
unsuccessful.  However, the oxidation proceeded smoothly under Jones oxidation 
conditions to furnish compound 80.  The phenol was deprotonated with sodium hydride to 
induce nucleophilic aromatic substitution but instead only starting material was returned up 
until 100 °C.  At higher temperatures the starting material decomposed.  We thought it was 
possible the sp2 hybridized carbonyl was restricting the ability of the molecule to orient itself 
properly to perform this substitution reaction.  The cyclization reaction was attempted on 
93 
 
 
Scheme 14. Attempts at nucleophilic aromatic substitution to make model system 82. 
 
compound 78, which allowed free rotation at this C-9 position.  However, this reaction 
returned starting material under 60 °C and decomposition above that temperature. Both of 
these cyclizations were also attempted with 2-bromopyridine (76) but there was no product 
formation. 
After several unsuccessful attempts on utilizing anion ring closures, our focus shifted 
toward radical cyclization.  Using our previously described reaction conditions for oxidative  
 
 
Scheme 15. Attempts at radical cyclization of compound 81 to 82. 
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ring closure of ellagitannins (Chapter 2) we found no conversion of 81 to 82 (Scheme 15).  
Cyclization with catalytic azobisisobutyronitrile (AIBN) as a radicial initiatior was also 
attempted; however, this reaction only returned the starting material.   
 Undeterred, our focus turned toward a Heck reaction to form this crucial aryl-aryl 
bond.  Initial efforts with the unprotected phenol led to a complex mixture of products.  The 
phenol was protected as methyl ether 83 using cesium carbonate and dimethyl sulfate 
(Scheme 16).  This precursor was subjected to standard Heck reaction conditions and 
cleanly afforded azafluorenone 84.36  The selectivity of this reaction can be explained by C-
9a being less sterically congested than C-4b.  
 
Scheme 16. Synthesis of azafluorenone 84 via a Heck coupling. 
 
The Heck reaction provided access to the azafluorenone scaffold, however this route 
led our efforts away from the synthesis of 4.  Instead of focusing on this natural product, we 
decided to develop a general synthesis of azafluorenone natural products.  Our approach 
was strategically different than any other azafluorenone synthesis and would provide an 
efficient route towards these compounds.  Due to the similarity of 82 to polyfothine (25), 25 
became our initial target.  The synthesis started with deprotonation of 4-methyl-3-
bromopyridine (83) with LDA, which was reacted with isovanillin (77, Scheme 17).  However, 
instead of deprotonation at the 3-position, lateral deprotonation occurred and afforded 
compound 86.   
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Scheme 17.  Unexpected reaction of 85 to form 87. 
 
This unexpected result made us re-examine our previous retrosynthesis.  We 
envisioned a similar reaction pathway as our previous method; utilizing the Heck reaction to 
close the ring and coupling between the pyridine anion and a benzaldehyde to tether the two 
components (Scheme 18).  We would selectively generate the anion on the 3-position of the 
pyridine with metal halogen-exchange. 
 
Scheme 18.  The retrosynthesis of compound 25. 
 
3-Bromo-4-methylpyridine (89) underwent metal-halogen exchange with n-BuLi 
which was then quenched with bromobenzaldehyde 9037 to give product 92 (Scheme 19).  
The benzyl alcohol was oxidized with MnO2 in 86% yield to give ketone 88.  The key Heck 
reaction proceeded smoothly to give us polyfothine (12) in moderate yield.38  The use of The 
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use of tetra-butylammonium chloride (TBAC) was instrumental in lowering the temperature 
and shortening the length of the Heck reaction.   
 
 
Scheme 19. The synthesis of polyfothine (12).  
 
The synthesis of polyfothine (12) also constituted a formal synthesis of 
azafluorenones 10 and 11.  When compound 12 was heated in 10 N HCl, demethylated 
products 10 and 11 were generated in 30% and 10% yield, respectfully (Scheme 20).14 
 
 
Scheme 20. The synthesis of 10 and 11 from azafluorenone 12. 
 
In order to test the scope and limitations of the newly designed methodology required 
the synthesis of a variety of different bromobenzaldehydes 94, 96 and 99.39,40,41  These 
compounds could adequately examine the substitution patterns at the R5, R6, R7 and R8 
positions (Scheme 21). 
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Scheme 21.  Synthesis of bromobenzaldehydes 94, 96 and 99. 
 
Following the previously described reaction conditions, ketones 88b-e were made 
without precedent (Scheme 22).  Unfortunately, cyclization with the Heck reaction was not 
general and slight alterations to the base, the temperature and the length of the reaction 
were necessary.  Ketones 88a-c afforded the desired azafluoreones.  However, when the R5 
or R8 position was substituted the Heck reaction failed.  Under our previous Heck reaction 
conditions the starting material was recovered, while using a stronger base or higher 
temperatures led to the dehalogenated starting material.  Due to the proximity of the R5 
substituent to the bromide it is believed that sterics were interfering with the palladium 
insertion.  One possible theory for the failure of the reaction with the R8 substituent has to do 
with the methoxy interfering with the transition state.    
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Aldehyde 
Yield 
(%) 88 
Heck Reaction 
Conditions 
Azafluorenone 
Yield 
(%) pdt 
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2
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, 
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47 % 
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99 
 
 
58 % 
 
Na
2
CO
3
, TBAC, Pd(OAc)
2
, 
DMF, 150 °C, 6 h 
 
 
 
- 
 
Scheme 22. Synthesis of azafluorenones 12, 23 and 1. 
 
In order to validate this hypothesis, the isoelectronic methylenedioxy derivative was 
synthesized.  Bromo-pyridine 89 underwent metal-halogen exchange and was quenched 
with the commercially available bromobenzaldehyde 101 (Scheme 23).  Oxidation with 
MnO2 gave ketone 103.  This compound was subjected to standard Heck reaction 
conditions and afforded a mixture of the azafluorenone product 104 and dehalogenated 
product 105.  From this information we could infer that the methoxy wasinterfering slightly 
with the reaction; however, there are other factors that were limiting the cyclization. 
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Scheme 23. Synthesis of methylenedioxy azafluorenone 104. 
 
In the future we would like to find general reaction conditions to facilitate ring closure 
with substitutions at the R5 and R8 positions.  One promising lead is the development of 
designer ligands for problematic palladium couplings.  One specific example is the use of 
DavePhos (107) to affect the transformation of 106 to fluorenone 108 (Scheme 24).42  This 
reaction did not work with standard Heck reaction conditions and required ligand 
optimization to receive acceptable yields.  DavePhos (107) was necessary because the 
bulky electron rich ligand facilitates both the oxidative addition step and the dissociation of 
the halide giving a more reactive palladium species.  
 
 
Scheme 24. Use of DavePhos (107) to improve yields of fluorenone 108 
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Our method for the synthesis of azafluorenones is strategically different than any 
known route to these molecules.  We provide an efficient and regioselective route towards 
the azafluorenone natural products.  Looking back on the 25 isolated azafluorenones, all of 
the examples except for one are within reach from this synthesis through optimization (Table 
2).   
 
Compound R2 R5 R6 R7 R8 Compound R2 R5 R6 R7 R8 
1
6
 H H H H H 14
7
 H OAc OMe OAc H 
2
8
 H H OMe H H 15
9
 H OH OMe H OH 
3
10
 H H OH H H 16
11
 H OMe OMe OH H 
4
12
 H OH OMe H H 17
11
 H OMe OMe OAc H 
5
10
 OMe H OMe OH H 18
11
 H OMe OMe OMe H 
6
10
 H OMe OMe H H 19
11
 H H H OH OMe 
7
10
 H H H H OH 20
11
 H H H OAc OMe 
8
10
 H OMe H H OMe 21
11
 H H H OMe OMe 
9
10
 H OAc OMe H H 22
13
 H OMe H H H 
10
14
 H H OH OMe H 23
13
 H H H OMe H 
11
14,15
 H H OMe OH H 24
13
 H H H H OMe 
12
14,15
 H H OMe OMe H 25
11,16
 H OMe OH H H 
13
7
 H OH OMe OH H       
 
Table 2.  The azafluorenone natural products.  The compounds highlighted in yellow are synthesized 
by our method, compounds in white could be synthesized by our method with optimization and 
compounds in red could not be synthesized directly by our method. 
 
Experimental: 
Deprotonation of 2-bromopyridine substrates: 
To a solution of DIPA (2.1 equiv) in THF (0.05 M), was added n-BuLi (2 equiv) at -78 °C.  
The mixture was warmed to -40 °C and stirred at this temperature for 45 min.  The solution 
was returned to -78 °C then the bromopyridine (1 equiv) was added dropwise and allowed to 
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stir at  -78 °C for 30 min.  Next, a solution of 3-hydroxy-4-methoxybenzaldehyde (1 equiv) in 
THF was added dropwise.  The reaction was allowed to warm up to rt over 10 h.  After 
completion of the reaction, it was quenched with water and extracted with EtOAc, washed 
with brine (10 mL) and dried over MgSO4, followed by filtration and concentrated in vacuo.  
The crude material was taken to the next step without further purification.   
Oxidation with Jones reagent: 
The alcoholic product (1 equiv) was dissolved in acetone (0.10 M) and Jones reagent (2 
equiv) was slowly added to the stirred solution at 0 °C.  The reaction was stirred for 1 hour 
at this temperature until completion, after which it was quenched with excess sodium 
bisulfite.  The solution was washed with water and extracted with diethyl ether.  It was 
washed with brine and dried over MgSO4, followed by filtration and concentrated in vacuo.  
The residue was purified with flash chromatography (2:1-1:2 hexanes:EtOAc).   
Methylation of phenol: 
To phenol (1 equiv) dissolved in DMF (0.10 M) was added Cs2CO3 (1.5 equiv) and the 
reaction was stirred for 10 minutes followed by the addition of dimethyl sulfate (1.2 equiv).  
The reaction mixture was heated to 60 °C for 18 h.  Upon completion the reaction was 
quenched with water followed by extraction with diethyl ether, washed with brine and dried 
over MgSO4, followed by filtration and concentrated in vacuo.  The residue was purified with 
flash chromatography (1:1 hexanes:EtOAc).   
Metal-halogen exchange: 
To a solution of 3-bromo-4-methylpyridine (89, 1 equiv) in THF (0.05 M) was added n-BuLi 
(1 equiv) at -100 °C.  The mixture was stirred at this temperature for 10 min followed by the 
addition of corresponding bromobenzaldehyde (1 equiv) as a solution in THF.  The reaction 
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was warmed up to -78 °C for 2 h and then stirred at rt for 8 h.  The reaction was quenched 
with water and extracted with EtOAc.  The organic phase was then washed with brine, dried 
over MgSO4, followed by filtration and concentration in vacuo. 
Manganese dioxide oxidation: 
To the crude alcoholic solution was added act. MnO2 (5 equiv) in benzene.  The solution 
was refluxed with a Dean Stark trap for 18 h.  The MnO2 was filtered off and the solution 
was concentrated in vacuo.  The residue was purified with flash chromatography (3:1-1:2 
hexanes:EtOAc). 
Heck reaction: 
A solution of bromobenzoylpyridines, TBAC (1.5 equiv), Pd(OAc)2, (0.1 equiv) and base (1.5 
equiv) in DMF (0.05 M) was heated and stirred until completion.  After the reaction was 
completed, the solutions were extracted with diethyl ether and washed with water, followed 
by brine and dried over MgSO4.  The organic phase was then filtered and concentrated in 
vacuo.  The residue was purified with flash chromatography (1:1-1:3 hexanes:EtOAc). 
 
5-((2-chloropyridin-3-yl)(hydroxy)methyl)-2-methoxyphenol (78): 1H NMR (300 MHz, 
CDCl3) δ  3.89 (s, 3 H), 5.63 (br, 1 H), 6.06 (s, 1 H), 6.81-6.92 (m, 3 H), 7.31 (dd, J = 4.8 Hz, 
J = 7.8 Hz, 1 H), 8.05 (dd, J = 2.4 Hz, 7.2 Hz, J = 1 H), 8.32 (dd, J = 1.8 Hz, 4.8 Hz, 1 H); 
13C NMR (100 MHz, CDCl3) δ 56.18, 72.17, 110.8, 113.5, 119.2, 123.0, 134.9, 136.9, 138.0, 
146.0, 146.7, 148.5, 149.7. 
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5-((2-bromopyridin-3-yl)(hydroxy)methyl)-2-methoxyphenol (79): 1H NMR (300 MHz, 
CDCl3) δ  3.90 (s, 3 H), 5.63 (br, 1 H), 6.03 (s, 1 H), 6.82-6.94 (m, 3 H), 7.36 (dd, J = 4.8 Hz, 
J = 7.5 Hz, 1 H), 7.99 (dd, J = 2.1 Hz, J = 7.8 Hz, 1 H), 8.30 (dd, J = 2.1 Hz, J = 4.8 Hz, 1 H); 
13C NMR (100 MHz, d-acetone) δ 56.76, 74.21, 112.6, 115.4, 118.8, 119.8, 124.8, 137.1, 
138.3, 143.0, 143.1, 147.8, 150.0. 
 
(2-chloropyridin-3-yl)(3-hydroxy-4-methoxyphenyl)methanone (80): 1H NMR (300 MHz, 
CDCl3) δ  3.96 (s, 3 H), 6.89 (d, J = 8.4 Hz, 1 H), 7.28-7.38 (m, 2 H), 7.40 (d, 2.1 Hz, 1 H), 
7.69 (dd, J = 1.8 Hz, J = 7.5 Hz, 1 H), 8.51 (dd, J = 2.1 Hz, 4.8 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 56.44, 110.3, 115.8, 122.4, 124.5, 129.7, 135.5, 137.9, 146.0, 147.9, 150.7, 151.9, 
192.1. 
 
(2-bromopyridin-3-yl)(3-hydroxy-4-methoxyphenyl)methanone (81): 1H NMR (300 MHz, 
CDCl3) δ  3.98 (s, 3 H), 6.90 (d, J = 8.7 Hz, 1 H), 7.31-7.40 (m, 2 H), 7.41 (d, 2.1 Hz, 1 H), 
7.63 (dd, J = 1.8 Hz, J = 7.5 Hz, 1 H), 8.49 (dd, J = 1.8 Hz, 4.8 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 56.45, 110.3, 115.9, 122.7, 124.7, 129.5, 137.2, 138.2, 138.7, 146.0, 151.0, 152.0, 
192.7. 
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(2-bromopyridin-3-yl)(3,4-dimethoxyphenyl)methanone (83): 1H NMR (300 MHz, CDCl3) 
δ  3.96 (s, 3 H), 3.97 (s, 3 H), 6.87 (d, J = 9.0 Hz, 1 H), 7.18 (d, J = 9.0 Hz, 1 H), 7.39 (m, 
1H), 7.59 (b, 1H), 7.66 (d, J = 3.0 Hz, 1 H), 8.51 (d, J = 3.0 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 56.29, 56.41, 110.2, 110.9, 122.6, 126.7, 128.8, 137.2, 138.2, 138.7, 149.7, 151.0, 
154.6, 192.6. m.p: 212-214 °C 
 
7,8-dimethoxy-5H-indeno[1,2-b]pyridin-5-one (84): 1H NMR (300 MHz, CDCl3) δ  3.97 (s, 
3 H), 4.05 (s, 3 H), 7.13 (t, J = 6.3 Hz, 1 H), 7.24 (s, 1 H), 7.41 (b, 1 H), 7.79 (d, J = 7.2 Hz, 1 
H), 8.48 (d, J = 5.4 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ  56.59, 56.89, 104.1, 106.9, 
122.7, 128.1, 129.4, 131.0, 138.5, 151.6, 152.8, 155.4, 164.9, 190.9; m/z: 242 [M+H]+, 121; 
HRMS: calcd. for C14H11NO3: 242.0812 [M+H]
+; found 242.0815. m.p: 219-221 °C 
 
5-(2-(2-bromopyridin-4-yl)-2-hydroxyethyl)-2-methoxyphenol (87): 1H NMR (300 MHz, 
CDCl3) δ  2.88-3.03 (s, 2 H), 3.90 (s, 3 H), 4.83 (t, J = 6.3 Hz, 1 H), 5.75 (br, 1 H), 6.74-6.83 
(m, 2 H), 6.93 (s, 1 H), 7.06 (d, J = 5.1 Hz, 1 H), 7.34 (s, 1 H), 8.21 (dd, J = 1.2 Hz, J = 5.1 
Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 44.57, 56.22, 74.09, 110.7, 112.2, 117.7, 124.3, 
129.2, 136.6, 142.3, 146.0, 146.6, 149.8, 150.9. 
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(2-bromo-4,5-dimethoxyphenyl)(4-methylpyridin-3-yl)methanone (88a): 1H NMR (300 
MHz, CDCl3) δ  2.51 (s, 3 H), 3.87 (s, 3 H), 3.93 (s, 3 H), 7.04 (d, J = 2.7 Hz, 1 H), 7.23 (d, J 
= 5.1 Hz, 1 H), 8.48 (s, 1 H), 8.56 (d, J = 5.1 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ  20.30, 
56.15, 56.34, 112.6, 113.0, 116.0, 126.4, 132.0, 133.7, 148.0, 148.3, 150.9, 151.6, 151.8, 
195.7; m/z: 336 [M+H]+; HRMS: calcd. for C15H14BrNO3: 336.023 [M+H]
+; found 336.0239 
 
(2-bromo-5-methoxyphenyl)(4-methylpyridin-3-yl)methanone (88b): 1H NMR (300 MHz, 
CDCl3) δ  2.58 (s, 3 H), 3.79 (s, 3 H), 6.89 (m, 2 H), 7.23 (d, J = 5.1 Hz, 1 H), 7.47 (d, J = 8.7 
Hz, 1 H), 8.48 (s, 1 H), 8.55 (d, J = 5.1 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ  20.46, 55.36, 
109.8, 114.8, 117.8, 126.4, 132.1, 134.0, 141.0, 148.5, 151.7, 151.9, 158.6, 195.8; m/z: 306 
[M+H]+, 276, 228, 121; HRMS: calcd. for C14H12BrNO2: 306.0124 [M+H]
+; found 306.013. 
m.p: 58-60 °C 
 
(2-bromophenyl)(4-methylpyridin-3-yl)methanone (88c): 1H NMR (300 MHz, CDCl3) δ  
2.59 (s, 3 H), 3.79 (s, 3 H), 7.25 (d, J=5.1 Hz 1 H), 7.43 (m, 3 H), 7.63 (d, J=7.5 Hz 1 H), 
8.47 (s, 1 H), 8.56 (d, J = 5.1 Hz 1 H); 13C NMR (100 MHz, CDCl3) δ  20.40, 119.6, 126.3, 
127.2, 129.5, 131.8, 132.2, 133.1, 140.2, 148.4, 151.5, 151.8, 195.9; m/z: 276 [M+H]+, 198, 
121; HRMS: calcd. for C13H10BrNO: 276.0019 [M+H]
+; found 276.0018   
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(2-bromo-3,4-dimethoxyphenyl)(4-methylpyridin-3-yl)methanone (88d): 1H NMR (300 
MHz, CDCl3) δ  2.53 (s, 3 H), 3.87 (s, 3 H), 3.95 (s, 3 H), 6.94 (d, J = 8.4 Hz, 1 H), 7.21-7.24 
(m, 2 H), 8.48 (s, 1 H), 8.56 (d, J = 5.1 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ  20.57, 56.35, 
60.75, 110.9, 117.1, 126.6, 126.9, 133.5, 133.9, 147.0, 148.4, 151.3, 151.8, 156.2, 195.6. 
 
(6-bromo-2,3-dimethoxyphenyl)(4-methylpyridin-3-yl)methanone (88e): 1H NMR (300 
MHz, CDCl3) δ  2.70 (s, 3 H), 3.71 (s, 3 H), 3.90 (s, 3 H), 6.90 (d, J = 8.7 Hz, 1 H), 7.24 (d, J 
= 5.1 Hz, 1 H), 7.29 (d, J = 8.7 Hz, 1 H), 8.55 (d, J = 5.4 Hz, 1 H), 8.57 (s, 1 H); 13C NMR 
(100 MHz, CDCl3) δ  21.06, 56.03, 61.49, 108.5, 114.6, 126.8, 128.1, 131.8, 135.9, 146.8, 
149.2, 152.2, 152.3, 152.6, 194.6. 
 
7-methoxy-4-methyl-5H-indeno[1,2-b]pyridin-5-one (12): 1H NMR (300 MHz, CDCl3) δ  
2.56 (s, 3 H), 3.85 (s, 3 H), 6.83 (d, J = 5.4 Hz, 1 H), 7.02 (dd, J = 8.1 Hz, J = 2.4 Hz, 1H), 
7.16 (d, J = 2.4 Hz, 1H), 7.67 (d, J = 8.1 Hz, 1H), 8.30 (d, J = 5.4 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ  17.6, 56.0, 109.1, 120.7, 122.3, 125.1, 126.2, 135.8, 137.1, 147.5, 153.0, 
162.5, 165.9, 193.3; m/z: 226 [M+H]+; HRMS calcd. for C14H11NO2: 226.0863 [M+H]
+; found 
226.0866. m.p: 137-138 °C; 
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9-methyl-10H-[1,3]dioxolo[4',5':4,5]indeno[1,2-b]pyridin-10-one (105): 1H NMR (300 
MHz, CDCl3) δ  2.63 (s, 3 H), 6.17 (s, 2 H), 6.90-6.94 (m, 2 H), 7.35 (d, J = 7.5 Hz, 1 H), 
8.39 (d, J = 5.1 Hz, 1 H). 
 
(5-bromobenzo[d][1,3]dioxol-4-yl)(4-methylpyridin-3-yl)methanone (103): 1H NMR (300 
MHz, CDCl3) δ  2.67 (s, 3 H), 6.00 (s, 2 H), 6.81 (d, J = 8.4 Hz, 1 H), 7.10 (d, J = 8.4 Hz, 1 
H), 7.26 (d, J = 5.1 Hz, 1 H), 8.59 (d, J = 5.1 Hz, 1 H), 8.64 (s, 1 H); 13C NMR (100 MHz, 
CDCl3) δ  21.02, 102.6, 110.4, 111.0, 122.7, 126.1, 126.9, 132.0, 146.7, 147.6, 149.4, 152.5, 
152.6, 192.3. 
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GENERAL CONCLUSION 
This dissertation has examined the synthesis and methodology development on the 
synthesis of tannins, flavonols and azafluorenones.   
The first chapter discusses a direct route to the total synthesis of (±)-1,3,4,5-
tetragalloylapiitol.  The synthesis was completed in 7 steps and allowed flexibility to allow for 
future derivatives to be made.   
Chapter two focused on the synthesis of natural and unnatural ellagitannins.  Our 
studies show the necessity of protection of the para-phenol of gallic acids to form the HHDP 
moiety via oxidative coupling.  Preliminary biological testing of the compounds shows good 
activity against HIV.   
The third chapter describes a base-mediated cyclization step towards the synthesis 
of flavonols.  This method constructs flavonols in the proper oxidation state without the 
necessity of harsh oxidizing agents. 
The fourth chapter examines a new synthetic route towards the synthesis of 
azafluorenones.  The synthesis utilizes a key intramolecular Heck coupling to form the 6-5-6 
scaffold.  Through optimization this synthesis could allow for the construction of almost all 
known azafluorenone natural products. 
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